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ABSTRACT 
Abhishek Venkatratnam: Inter-individual differences in trichloroethylene toxicokinetics and 
toxicodynamics in genetically-diverse mice.  
(Under the direction of Ivan Rusyn) 
One of the many challenging issues in toxicology is addressing human variability in 
chemical risk assessment. Among several intrinsic and extrinsic factors that contribute towards 
inter-individual differences in toxic responses, genetic differences are well known to drive 
variability in xenobiotic metabolism and adverse effects. Traditional toxicity studies in rodents 
often rely on single genotype-based models that fail to capture diverse responses similar to those 
observed in humans. Recent advances in mouse genetics have led to the development of large 
panels of recombinant lines collectively known as population-based mouse models. Although their 
utility in biomedical research has been sufficiently demonstrated, their application in toxicity 
studies needs to be investigated. My doctoral dissertation focuses on investigating inter-individual 
differences in toxicokinetics (TK) and toxicodynamics (TD) in population-based mouse models 
with trichloroethylene (TCE) as case study toxicant. The central hypothesis of my dissertation is 
that genetic differences in the mouse population will drive inter-individual differences in TCE 
metabolism and related effects. Aim 1 demonstrated sufficient statistical power and precision in 
the mouse population to identify genetic loci driving variability in TCE metabolism and TD. Next, 
extent of quantitative variability in some toxicokinetic parameters were comparable to those 
observed in humans suggesting the appropriateness of such model in addressing human variability 
in adverse outcomes. Aim 2 characterized transcriptional responses that were strongly influenced 
by genetic background, dose, or a combination of genetic background and dose to better 
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understand individual- versus population-level responses. Aim 3 assessed the utility of different 
population-based models in capturing diverse responses in a standard 90-day oral toxicity study 
that is often conducted for safety assessments. Collectively, this doctoral dissertation serves as a 
comprehensive guide in incorporating population-based mouse models in toxicity studies.  
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CHAPTER 1: INTRODUCTION 
I. Risk assessment of chemicals 
Regulation of human exposure to toxic substances has been in existence for more than a 
century. The Pure Food and Drug Act of 1906 (enacted by the 59th US Congress) included 
consumer protection laws and established the Food and Drug Administration. It was 
replaced/amended by the US. Federal Food Drug and Cosmetic Act in 1938 (75th US Congress) 
(Barkan, 1985). In 1970s, a key initiative by the U.S. Food and Drug Administration was the 
establishment of the National Center for Toxicological Research that serves as a hub of studying 
health effects with chemicals. Since then, exposure to chemicals, toxicants, or pharmaceuticals has 
raised concerns of adverse health effects in humans, thereby, prompting the need for a regulatory 
framework to address risk associated with such exposures. Human health risk assessment involves 
systematic processes that aim to characterize the association of health effects with chemical 
exposures to aid with regulatory decisions regarding public health. Risk assessment models predict 
and create awareness of risk associated with particular chemical exposures and helps prioritize 
control measures in case of accidental release into the environment (Leeuwen & Hermens, 1995). 
Four components of risk assessment are hazard identification, dose-response assessment, exposure 
assessment, and risk characterization. For the purposes of this dissertation work hazard 
identification and dose-response components of risk assessment will be discussed below.
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I.A. Hazard identification 
Hazard identification is the qualitative assessment that aims to understand the nature of 
adverse health effect caused by chemicals.  The cause-effect relationship is established based on 
epidemiological data, in vitro models or rodent carcinogenicity bioassay data. Epidemiological 
studies may aid in deriving associations between a chemical and an adverse health outcome 
(cancer, reproductive, or developmental toxicity) and play a crucial role in risk assessments 
(Adami et al., 2011). As epidemiological data are often unavailable for most chemicals due to 
challenges with assessing exposures, rodent bioassays are the most common method to identify 
hazards associated with chemical exposures. In these bioassays, mice and rats of both sexes are 
exposed to repeated doses of the chemical of interest and signs of both cancer and non-cancer 
toxicities are examined (Bucher, 2002). The findings from these studies are based on the general 
assumption that rodent assays are good models of humans (King-Herbert & Thayer, 2006). Across 
different regulatory agencies including the U.S. EPA, there is a general need to prioritize toxicity 
testing of chemicals (Dix et al., 2007). With the advancement in high throughput screening (HTS), 
the U.S. EPA initiated a research program titled “Toxicity Forecaster” or ToxCast™ that focuses 
in the development of a rapid and inexpensive platform to predict toxicity in chemicals based on 
bio-activity profiling (Knight et al., 2009). Previous studies have demonstrated the usefulness of 
ToxCast™ data to prioritize chemicals for hazard identification (Reif et al., 2010; Sipes et al., 
2011). 
Underlying biochemical events that are perturbed to cause an adverse effect with exposures 
are called mechanisms of action. Understanding the mechanism of action (MOA) helps to 
characterize a hazard because the relevance of such mechanisms across species can be considered 
when extrapolating findings from rodents to humans. Currently, evidence for mechanisms of 
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action for chemicals are often gathered using mechanistic models that rely on knock-out, knock-
in, or humanized rodent models thereby identifying critical pathways of toxicity (Boverhof et al., 
2011).  
I. B. Dose-response assessment  
Dose-response assessment in environmental toxicology often aims identify a point of 
departures (PoD) which is a point on the dose-response curve that is often used to derive an 
estimate of the low dose at which adverse health effects are expected to occur. With the use of 
epidemiological data, the dose can be established based on direct observations of health effects in 
humans. In the absence of human data, lowest doses are extrapolated based on data from rodents 
to humans. A persistent challenge in this approach is that the shape of the dose-response curve is 
vastly influenced by the degree of variability and uncertainty associated with the available data, 
often leading to inaccurate dose estimates (National Research Council, 2009).  
II. Variability and uncertainty in components of risk assessment 
Uncertainty in risk assessment arises due to lack of data or incomplete information 
(National Research Council, 2009). Uncertainty exists in all components of risk assessment 
(WHO, 1995).  In theory, uncertainty will always exist due to gaps in knowledge and can only be 
minimized based on the quality, quantity, relevance of data, and the inferences applied towards 
risk assessment (2009). For example, appropriateness of the animal model and reliability of assays 
may significantly contribute to uncertainty in hazard identification. Differences in the 
mathematical models applied in capturing shapes of dose-response curves can result in large 
uncertainty associated with dose-response assessments. . Uncertainty in estimating tissue-specific 
internal doses of chemicals also poses a challenge in exposure assessments.  
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Variability refers to differences in responses due to heterogeneity within a species or 
population. Unlike uncertainty, variability cannot be minimized but can only be better 
characterized (National Research Council, 2009). Biological variability in responses arises from 
both intrinsic and extrinsic factors. These include hereditary factors (genetics or epigenetics), sex, 
age, pre-existing conditions, co-exposures, diet etc. (Zeise et al., 2013). Several studies have 
reported that exposures to pharmaceuticals in humans show inter-individual differences in 
responses leading to variable susceptibility to toxicity and adverse effects (Harrill, Watkins, et al., 
2009; Hattis, Erdreich, & Ballew, 1987; Kwara et al., 2009). Further, as these responses can be 
qualitatively or quantitatively different in a population, addressing variability is critical in properly 
characterizing risk in human health risk assessments.  
II.A. Traditional methods to address variability and uncertainty in risk assessment  
Two approaches have been widely used to address uncertainty in risk assessment 
(Richardson, 1996). 
Deterministic approach – In this approach each parameter or variable used in risk 
assessment processes is considered as a point estimate and uncertainty is addressed by using 
conservative assumptions. A common approach used by regulators to address uncertainty is to rely 
on defaults. In simple terms, defaults are inference guidelines that aid in the completion of risk 
assessment in the absence of chemical- or endpoint-specific data. Defaults are applied in cases 
when insufficient or lacking data lead to critical data gaps, in a manner to facilitate the risk 
assessment process (National Research Council, 2009).  Use of safety factors is an example of 
applying defaults to address uncertainty due to data gaps in assessment. Traditionally, an 
uncertainty or safety factor of 100-fold is applied to establish no observed adverse health effect 
level (NOAEL) data from chronic rodent studies to humans (Dourson, Felter, & Robinson, 1996; 
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Lehman, 1954). A 10-fold factor is applied to account for intra-species variability in toxicokinetics 
(TK) and toxicodynamics (TD) (100.5=3.16 for each of these parameters). Another 10-fold factor 
accounts for variable response in human population. The use of defaults have always been a subject 
of debate as to whether it underestimates or overestimates risk estimates derived from rodent data. 
Depending on availability of data, the uncertainty with toxicity values can been reduced. Although 
efforts to address uncertainty using defaults have long existed, there is a need to develop better 
approaches to minimize uncertainty in risk assessments. 
Probabilistic and statistical approach – Probabilistic and statistical approaches are 
perceived to be more realistic in deriving risk estimates and so have gained popularity in recent 
years. Benchmark dose (BMD) analysis is a useful metric to determine safe chemical exposure 
levels and deals with deriving NOAEL (Geter, Bhat, Gollapudi, Sura, & Hester, 2014). 
Traditionally, this analysis aims to establish dose-response relationships based on data on apical 
endpoints from sub-chronic or chronic rodent toxicity studies. In a statistical approach, uncertainty 
factors are implemented to derive safe estimates. In a probabilistic approach, each parameter from 
the rodent data is derived as a probability density function to provide a range of risk estimates. 
Although no clear guidelines are available in identifying the right numerical techniques to provide 
a risk distribution, use of computational approaches such as Monte Carlo Simulations, are more 
commonly implemented to assist with such applications.   
Monte Carlo Simulation (MCS) – MCS is a numerical approach that involves repeated 
random sampling to generate results. It has been primarily implemented in risk assessment 
processes to address and minimize uncertainties in toxicokinetic responses with chemical 
exposures. Physiologically-based-pharmacokinetic (PBPK) models are mathematical models that 
are used to predict dose-time relationships of chemicals. These models are conceptually driven by 
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mass balance equations and can be multi-compartmental in nature to address complex TK profiles 
in different tissues. MCS is applied in PBPK models by randomly selecting values for each 
parameter in a mass-balance equation while keeping other parameters in the equation fixed. This 
process is repeated several times, until a probability distribution for each parameter is acquired, 
leading to range of estimates. 
Although these approaches to address uncertainty in assessments have evolved over time, 
efforts to address variability still remains in infancy. It is evident that biological variability in toxic 
responses arise from several sources. Although it is difficult to identify the specific factor/s driving 
variability, the need to develop models to address variability is important and relevant to human 
health assessments. Several cases from the pharmaceutical industry have shown over the last 
decade that genetic variants or single nucleotide polymorphisms (SNPs) result in large variability 
in xenobiotic metabolism and drug-induced toxic effects (R. B. Kim, O'Shea, & Wilkinson, 1994; 
Krueger & Williams, 2005; Lanfear & McLeod, 2007). As classical rodent models are based on 
single strains or genotypes of rats and mice, the heterogeneous responses as observed in humans 
are often poorly captured in such models. Further, extrapolation of data from these rodent models 
to humans often raises questions as to whether data acquired in single strains of rodents are indeed 
reflective of sensitive individuals in the human population.  
II. B. Individual- versus population-based risk assessment 
Variability in human susceptibility to chemicals is a persistent challenge in risk 
assessments. As toxicity data in single-strain rodent models have been historically extrapolated to 
humans, variability in these responses due to genetic differences within the rodent species needs 
to be assessed to understand the divergence of derived toxicity values from their true values. One 
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critical concern with these extrapolations is that whether the rodent strain used in toxicity testing 
is a good model in mimicking qualitative and quantitative responses as observed in the susceptible 
groups or individuals in humans. Figure 1.1 shows an illustration depicting the relevance of 
incorporating susceptible individuals in toxicity testing. This figure demonstrates that within any 
population in a species there will be individuals or sub-groups that demonstrate higher risk to 
adverse health effects with exposures. Thus, use of susceptible individuals from one population 
may serve as good models to enhance hazard identification with chemical exposures. 
Some environmental chemicals are known to interact with several biological targets 
suggesting the possibility of multiple mechanisms of action underlying elicited adverse outcomes. 
As toxicological assessments of these chemicals are often conducted in single rodent strains 
whether a particular mechanism of action for a chemical is predominant in the population or 
susceptible groups or individuals remains unaddressed (Figure 1.2). This figure shows that two 
individuals in a population may demonstrate different dose-response relationships for identical 
exposure suggesting that population-level differences in the underlying mechanisms of responses 
needs to better understood. This information would then be useful in understanding inter-
individual differences in toxic outcomes and also help build confidence in addressing human 
variability in risk assessments. Figure 1.3 shows a graph that demonstrates the significance of 
understanding population average responses. Herein, we observe that individuals in a population 
showing different degrees of effects. It is perceived that data from epidemiological and rodent 
studies provide risk estimates of population median; but information on whether population 
median and average differ significantly may be relevant in risk assessments. Despite understanding 
the limitations in existing models to assess risk with exposures, efforts to improve existing models 
to address variability is critical.    
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III. Implementation of emerging sciences and technologies to improve risk assessment 
        The objective of toxicity testing is to assess risk posed to humans by chemical exposures.  
Current approaches of toxicity testing originate nearly half a century ago at a time when knowledge 
on the biological hierarchy of signaling was in its infancy (Bhattacharya, Zhang, Carmichael, 
Boekelheide, & Andersen, 2011). In the last decade, numerous reports have highlighted the 
persistent challenges with current approaches of toxicity testing (National Research Council, 2007, 
2009). For instance, in 2007 the National Research Council (NRC) outlined a far-reaching vision 
to incorporate emerging sciences and technologies in toxicity testing to better aid with 
characterization and identification of hazard. In 2009, NRC also published a book titled “Science 
and Decisions” emphasizing better approaches to address uncertainty and variability in scientific 
data to improve public health assessments. Additional reports have supported incorporating 
advances in molecular and systems biology into risk assessment practices (Andersen & Krewski, 
2009; Cote et al., 2012). 
III.A. Advances in mouse genetics that aid in the characterization of population-level 
health assessment 
Rodent models have been widely implemented in biomedical research due to their 
supposed physiological similarities with humans (Roberts & Threadgill, 2005). These models are 
relatively inexpensive and can be generated in large quantities in a short period of time. Rodents 
are easily housed and handled during agent administration and sample collection procedures. 
Among different rodents, mice and rats are most common species for toxicity testing.  
Laboratory mice have been historically used to study cancer, genetics, chronic diseases, 
infectious diseases, biomarker discovery, and other biomedical applications. In toxicology, mice 
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have been used to identify hazards and characterize dose-response relationships (OECD, 1996). 
Early advances in genetics enabled knock-out of specific genes thereby facilitating the 
development of mechanistic mouse models (Donehower, 1996). Later developments in genetics 
led to the creation of ‘humanized’ mice where functionally-active genes, cells or tissues from 
humans have been inserted into mice to characterize inter-species differences in dose-response 
relationships (Dorner et al., 2011). Despite significant progress in mouse genetics, efforts to 
develop mouse populations to characterize human genetic variability in adverse reactions remained 
unestablished through the early 2000s. For instance, although use of mouse diversity panels since 
2000s involve the use of multiple strains, they are genetically close to each other due to historical 
breeding strategies from common stocks. Further, the use of population-based mouse models in 
biomedical research have demonstrated their utility in identifying genetic markers for complex 
traits but are yet to be adopted in the risk assessment processes.  
In 2004, mouse geneticists developed a community resource to establish a reference panel 
of mice for integrating complex analysis to address human variability in adverse outcomes and 
diseases (Churchill et al., 2004). The Collaborative Cross (CC) is large panel of recombinant 
inbred lines derived from a genetically-diverse set of founder strains. Due to the breeding strategy 
the genomic structure of each CC line is a mosaic representation of genetic variants from the 
founder strains. Further, each CC line offers abundant genetic diversity by retaining a single 
nucleotide polymorphism (SNP) for every 100-200 bp thereby representing genomic structure as 
observed in humans (Churchill et al., 2004). Thus, the CC is a genetically-diverse and a 
reproducible model that may be useful in characterizing inter-individual differences in 
toxicokinetic and toxicodynamic responses with exposures. 
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In 2012, another population-based rodent model was developed from the CC model 
(Churchill, Gatti, Munger, & Svenson, 2012). The Diversity Outbred (DO) are F2 generation of 
randomly selected CC strains. Consequently, each DO mouse is heterozygous in its genotype and 
unique, and more similar to humans. Several studies have utilized DO populations to identify 
genetic drivers of variability in responses (Church et al., 2015; French et al., 2015; Smallwood et 
al., 2014). One major concern with DO is that the model is not reproducible and data produced 
from these models may be highly variable due to batch-to-batch differences in their genetic 
diversity.   
Few studies have utilized the F1 intercrosses of CCs also known as CC recombinant 
intercrosses (RIXs) as a mouse population model for humans (Green et al., 2016a; Green et al., 
2016b). CC RIXs are heterozygous in their genotypes and unlike the DO are reproducible.  
Although the different mouse populations described above have been used in several biomedical 
applications, their usefulness in toxicity testing is just starting to be evaluated. 
III.B. Incorporation of genetic data to improve health assessment   
 Population geneticists have often employed scientific and technological advances relevant 
to the central dogma of molecular biology to draw connections between variability in a phenotype 
and genotype (Doerge, 2002). As many phenotypes or traits are often complex or driven by 
multifactorial elements, it is often required to identify all the regions in the DNA responsible to 
characterize total phenotypic variability in a population. Quantitative trait loci (QTL) is the region 
of DNA identified by a statistical analysis that is associated with the variability of a phenotype in 
a population. 
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Advances in next-generation DNA sequencing technologies have led to the rapid collection 
of genomic sequence information from individuals in a population to facilitate genotype-
phenotype association analysis (Lappalainen et al., 2013). Human genome-wide association 
studies (GWAS) have enabled identification of genetic factors associated with metabolic diseases, 
drug metabolism and efficacy, and biomarkers of toxicity (Duerr et al., 2006). The underlying 
basis of GWAS is that SNPs can exert influence on a trait either due to a functional change in the 
protein sequence or in the rate of transcription. Although human GWAS is a powerful approach in 
identifying common genetic variants with risk of adverse effects, poor characterization of 
environmental exposures can lead to issues identifying risk-specific genetic factors. As rodent 
studies are always conducted in controlled environments, implementing population-based rodent 
models will help in accurately characterizing gene-environment interactions.           
III.C. Pathway-based approaches to understand variability in mechanisms of action 
In the last decade, transcriptomic approaches have been frequently applied in the field of 
toxicology to advance risk assessment by providing molecular insights on the mode of action of 
pharmaceuticals or chemicals (Burczynski et al., 2000; Harrill & Rusyn, 2008; E. Y. Xu et al., 
2008). Traditional transcriptomic-based studies often aim to identify genes perturbed with 
treatment and provide little or no information on dose-expression relationships (Heijne, Stierum, 
Slijper, van Bladeren, & van Ommen, 2003; Robinson et al., 2010). Recent studies have provided 
strong evidences to support the incorporation of transcriptomic-dose response data for hazard 
identification or dose-response assessment (Andersen, Clewell, Bermudez, Willson, & Thomas, 
2008; Thomas, Philbert, et al., 2013b). Combining pathway analysis with dose-expression 
responses can help identify sensitive cellular pathways and establish reference doses at which 
pathways are perturbed by treatment (Thomas et al., 2007a). Due to the high cost associated with 
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conducting two-year cancer bioassays, studies have shown that PoDs from gene expression data 
from acute toxicity studies may be used as an alternative to apical endpoints to establish dose-
response relationships (Bercu et al., 2010; Thomas et al., 2007a; Thomas et al., 2012).  
 
IV. Critical problem in human health risk assessments  
Chemical risk assessments aid in informing the public on hazard associated with exposures. 
Addressing human variability in susceptibility to toxic effects is a persistent unmet need in risk 
assessments. Evidences suggests that use of uncertainty factors to address inter-individual 
responses in toxicokinetics and toxicodynamics may not cover human variability that arise from 
genetic polymorphisms (Dalen, Dahl, Bernal Ruiz, Nordin, & Bertilsson, 1998; Dorne, Walton, & 
Renwick, 2003, 2005; Harrill, Watkins, et al., 2009). Due to limited genetic diversity, current 
mouse panels have limited precision in identifying genetic factors that aid in the characterization 
of variability in mechanisms of toxicity in a population. Current approaches in evaluating 
variability in responses often are poorly rationalized in terms of selection of strains, study designs, 
and end points investigated to establish dose-response relationships. Existing models lack the 
power to implement systems genetic approaches in drawing connections between variability in 
toxic responses and molecular events. Further, toxicity testing for regulatory purposes employs 
single strains of rodents to identify and characterize chemical-specific effects. Such practices in 
toxicological studies highlight the critical need in evaluating and characterizing variability in 
toxicodynamic and toxicokinetic responses using population-based rodent models.  
Population-based rodent studies are often expensive, tedious, and labor intensive. Although 
previous studies using population-based rodent models exist, their relevance to regulatory 
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toxicology is difficult to establish. Thus, the overall objective of this doctoral dissertation is to 
serve as a systematic guide in conducting population-based rodent studies and provide relevant 
information to improve human health assessments. Several toxicokinetic and toxicodynamic 
studies were conducted to fully characterize variability in responses driven by a case-study toxicant 
trichloroethylene. 
V. Trichloroethylene (TCE) as a case study toxicant 
  Despite toxicological information gathered over several decades, TCE is still one of the ten 
chemicals that will be evaluated for potential risks to human health under The Toxic Substances 
Control Act (TSCA), amended by the Frank R. Lautenberg Chemical Safety for the 21st Century 
Act in 2016. TCE is a chlorinated solvent that is colorless, odorless, volatile, and insoluble in 
water. It was initially produced in large quantities in the 1920s in Germany and United States with 
the primary application as a degreasing agent in industrial operations (Cotter, 1950). Due to poor 
waste disposal practices of TCE it is recognized as a ubiquitous environmental contaminant and 
found in elevated levels in soil and ground water. Its high volatility poses chronic human health 
risk with exposures in residential and public spaces. 
V.A. Health hazard with TCE  
TCE is associated with both cancer and non-cancer adverse health effects (Rusyn et al., 
2014). Previous occupational studies have shown strong positive associations between TCE 
exposure and kidney cancer in humans (McGregor, Heseltine, & Moller, 1995). Studies in rats 
have shown increased incidences of kidney tumors with TCE exposures across both sexes 
(National Toxicology Program, 1988). Epidemiological Studies have also shown positive 
association between TCE exposure and non-Hodgkin lymphomas (Guha et al., 2012). In mice, 
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exposure to TCE has led to statistical increases in the formation of liver tumors (Bull et al., 2002). 
The International Agency for Research on Cancer (IARC) classifies TCE as Group 1 chemical, 
carcinogenic to humans, based on strong epidemiological evidence for kidney cancer and 
mechanistic evidence from animal studies (Guha et al., 2012; IARC, 2014).       
V.B. Metabolism of TCE 
The majority of adverse effects from TCE exposures are associated with its metabolites. 
TCE is primarily metabolized by two major pathways (Figure 2.1) in both rodents and humans – 
the Cytochrome P450 (CYP) dependent oxidation and glutathione (GSH) conjugation. Although 
oxidative metabolism of TCE takes place primarily in the liver, it can also occur in lung, kidney 
and other organs (Cummings & Lash, 2000; Forkert, Lash, Nadeau, Tardif, & Simmonds, 2002; 
Odum, Foster, & Green, 1992). Among many metabolites generated in the oxidative pathway, 
trichloroacetic acid (TCA) and dichloroacetic acid (DCA) are associated with formation of liver 
tumors in mice (Bull, Sanchez, Nelson, Larson, & Lansing, 1990). Glutathione-dependent 
metabolites of TCE are further biotransformed to reactive intermediates that are associated with 
kidney toxicity (Lash, Fisher, Lipscomb, & Parker, 2000).  Quantitative differences in levels of 
TCE metabolites are known to exist between species and may contribute to inter-species 
differences in TCE adverse effects (Rusyn et al., 2014). PBPK modeling has shown that the 
quantitative extent of variability in oxidative metabolites are similar in target tissues among both 
humans and mice (Chiu et al., 2014a). 
Previous reports suggest that specific metabolites of TCE can act by either genotoxic or 
non-genotoxic mechanisms of toxicity on target tissues (Chang, Daniel, & DeAngelo, 1992; 
Dekant et al., 1986; Giller, Le Curieux, Gauthier, Erb, & Marzin, 1995; Vamvakas, Elfarra, 
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Dekant, Henschler, & Anders, 1988; Y. C. Zhou & Waxman, 1998). For instance, it is well known 
that TCA and DCA are peroxisome proliferator-activated receptor α (PPARα) activators that 
induce peroxisome proliferation and hepatocellular proliferation in rodents. The glutathione-
dependent metabolite S-(1, 2-dichlorovinyl) glutathione (DCVG) is known to exhibit genotoxic 
mechanism of action in the kidney (Vamvakas et al., 1988).  
Inter-individual differences in TCE toxicokinetics and toxicodynamics have been 
previously investigated in both rodents and humans. Studies in humans have shown inter-
individual differences in TCE toxicokinetics suggesting the existence of susceptibility to TCE 
toxicity (Ertle, Henschler, Muller, & Spassowski, 1972; Muller, Spassovski, & Henschler, 1974; 
Muller, Spassowski, & Henschler, 1975). Rodent studies have demonstrated inter-strain 
differences in oxidative and GSH-dependent metabolite levels suggesting dominance of different 
mechanisms of action for each strain with repeated TCE exposures (Bradford et al., 2011). This 
evidences suggest that inter-individual variability in adverse responses exists in both rodents and 
humans. However, there is a need to better characterize variability by identifying genetic drivers 
underlying these responses. 
VI. Rationale and Specific Aims  
VI.A. Choice of population-based rodent resource 
 Among different population-based rodent models available, we selected the CC model for 
most of our studies for several reasons. First, the CC is a large panel of recombinant inbred lines 
that provides sufficient statistical power to perform systems genetic analysis. Second, the model 
is reproducible and so the findings from our studies can be repeated to establish data 
reproducibility. Third, the genetic data of the CC population is well curated to perform genetic and 
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genomic analyses.  In order to evaluate variability between different models one of our studies 
involved using CC, DO, and CC-RIX strains to assess models with large variability in toxic effects. 
VI.B. Choice of case-study toxicant 
 Trichloroethylene was selected as the case study toxicant for our studies. First, TCE is a 
known carcinogen in both humans and mice. Evidences of inter-individual differences in TCE 
metabolism and toxicity has been reported in both humans and mice (Muller & Spassows.M, 1973; 
Yoo, Bradford, Kosyk, et al., 2015b). Exposure to TCE generates metabolites that are associated 
with organ-specific cancer toxicities, and PBPK modeling has shown that the quantitative extent 
of variability in these metabolites is similar in target tissues among both humans and mice (Chiu 
et al., 2014b).  
VI.C. Choice of study designs 
 We conducted single-dose acute toxicity studies to characterize toxicodynamic and 
toxicokinetic responses. We also conducted a 90-day oral toxicity study in close accordance to the 
OECD guidelines to evaluate variability in toxic responses within and between different 
population mouse models in reference to B6C3F1. 
VI.D. Specific Aims 
Aim 1: To evaluate and characterize inter-individual differences of TCE metabolism in CC  
Hypothesis: Inter-individual differences in TCE metabolism are driven by genetic diversity in the 
CC model   
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Aim 2: To evaluate and characterize inter-individual variability in liver gene-expression 
responses in CC  
Hypothesis: TCE exposure causes differential expression of genes in the liver in a dose-, strain-, 
and dose*strain- dependent manner 
Aim 3: To evaluate inter-individual differences in TCE metabolism and toxicity in a 90-day 
oral toxicity study using genetically-diverse mouse populations. 
Hypothesis: We hypothesize that inter-strain differences in responses within different mouse 
populations will be highly variable compared to intra-strain variability in B6C3F1 mice, and will 
exhibit wide variability in TCE toxicity from sub-chronic exposures will be observed.  
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VII. Figures and Tables 
Figure 1.1. An illustration depicting susceptible individuals from two species to risk with 
exposures. 
 
 
 
 
 
 
Figure 1.2. A sketch depicting two individuals showing different dose-response relationships with 
identical exposure. 
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Figure 1.3. An illustration depicting individual versus population dose-response relationships.
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CHAPTER 2: EVALUATION AND CHARACTERIZATION OF INTER-INDIVIDUAL 
DIFFERENCES IN TCE METABOLISM1 
I. Introduction 
Addressing population-level variability in susceptibility to toxic effects of environmental 
exposures is a persistent unmet need in human health assessments (Zeise et al., 2013). Traditional 
toxicity testing is conducted in a single isogenic strain of laboratory rodents (Festing, 1986), which 
complicates the extrapolation to the heterogeneous human population. Recent studies 
demonstrated the utility of the mouse population-based approach for quantitative evaluation of the 
variability in metabolism and toxicity (Bradford et al., 2011; Chiu et al., 2014a; French et al., 
2015), characterization of the susceptibility mechanisms (Harrill, Watkins, et al., 2009; Koturbash 
et al., 2011; Yoo, Bradford, Kosyk, et al., 2015a; Yoo, Bradford, Kosyk, Uehara, et al., 2015), and 
mapping of the loci that may confer susceptibility to toxicants (Church et al., 2015; French et al., 
2015; Harrill, Watkins, et al., 2009). 
The use of population-based mouse models in experimental biomedical research have 
flourished with the recent advancements in mouse genetics and the availability of the Diversity 
Outbred (DO) and Collaborative Cross (CC) populations (Aylor et al., 2011; Bogue, Churchill, & 
Chesler, 2015). These mouse populations were designed to randomize genetic variation so that all 
components of systems can be interrogated as allele frequencies are ideal for quantitative trait   
                                                          
1 The text from this chapter is reproduced with permission from Toxicological Sciences 158(1): 48-62 (2017). 
Oxford University Press © 2017. 
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locus (QTL) mapping; they are also sufficiently large to power analyses of modest interactions 
(Threadgill & Churchill, 2012). The genome of each CC and DO line represents a mosaic of eight 
parental inbred strains distributed randomly across the genome; however, because CC lines have 
been inbred they carry an advantage of infinitely reproducible model to support data integration 
and reproduction across laboratories, chemicals and study designs (Threadgill & Churchill, 2012). 
The CC mouse model has been highly efficient in identifying candidate genetic markers 
responsible for several pathophysiological conditions, genetic analysis of complex traits, 
identification of novel gene functions, and modeling emergent diseases (Aylor et al., 2011; Durrant 
et al., 2011; Ferris et al., 2013; Kovacs et al., 2011; Rasmussen et al., 2014; Rogala et al., 2014).  
Experimental toxicology is poised to make use of the CC population for investigations of 
the genetic and molecular determinants of inter-individual variability in toxicokinetics and 
toxicodynamics. For example, quantitative assessment of inter-individual variability in 
metabolism of several environmental contaminants of major public health relevance, such as 
chlorinated solvent trichloroethylene (TCE), is among the critical needs for human health 
assessments (Cichocki et al., 2016). TCE is a ubiquitous environmental chemical and is a 
carcinogen in humans (Rusyn et al., 2014). It is primarily metabolized (Figure 1) by the 
cytochrome P450 (CYP) system and glutathione conjugation generating qualitatively similar 
metabolites in both humans and rodents (Lash, Chiu, Guyton, & Rusyn, 2014). Among the 
metabolites of TCE, trichloroacetic acid (TCA) is the prevalent oxidative metabolite and a known 
peroxisome proliferator-activated receptor alpha (PPARα) agonist that is thought to be one of the 
key drivers of TCE toxicity (Bull et al., 1990; Chiu et al., 2013; Corton, 2008). Previous studies 
have demonstrated inter-individual differences in oxidative TCE metabolism and toxicity in 
humans (Muller et al., 1974; Muller et al., 1975) and multi-strain studies in mice (Bradford et al., 
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2011; Yoo, Bradford, Kosyk, et al., 2015a; Yoo, Bradford, Kosyk, Uehara, et al., 2015). 
Interestingly, PPARα-mediated pathways, including the metabolism genes induced by TCE, are 
among the most distinct effects that are dependent on genetic background (Bradford et al., 2011). 
The objective of this study was to evaluate the extent of inter-strain variability in the 
oxidative metabolism of TCE, and to identify loci that may be driving these differences. We 
hypothesized that genetic diversity affects inter-strain differences in TCE metabolism and toxicity. 
We conducted a dose– response (0, 24, 80, 240, or 800 mg/kg of TCE) study in 50 CC strains. 
Inter-strain variability in TCA levels, as well as protein or activity levels of several TCE-
metabolizing enzymes, was examined in the CC mouse population at 24 h after dosing. We 
identified several QTLs associated with variability in TCE metabolism that provide genetic 
evidence for the role of PPAR pathway in the oxidative metabolism of TCE. 
II. Materials and methods 
Animals and treatments. Adult male mice (8–12 weeks old) from 50 CC strains were 
acquired from the University of North Carolina Systems Genetics Core (Chapel Hill, NC). Animals 
were fed an NTP 2000 wafer diet (Zeigler Brothers, Inc., Gardners, PA) and water ad libitum. The 
housing room was maintained on a 12-h light–dark cycle. Animals were allowed to acclimate to 
the room for at least 10 days prior to beginning experimentation. The experimental design sought 
to maximize the number of strains relative to within-strain replications based on the power analysis 
for QTL mapping in mouse populations (Kaeppler, 1997); therefore, one mouse was used per 
strain/dose group. Male animals were used because maximal rates of TCE oxidative metabolism 
in rodents differ between males and females, higher concentrations of CYP-derived metabolites of 
TCE were found in livers of males than in females (Lash, Putt, & Parker, 2006). Mice were orally 
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administered a single dose of 0, 24, 80, 240, or 800 mg/kg TCE (Sigma Aldrich, St. Louis, MO) 
in 5% Alkamuls EL620 vehicle (Solvay, Deptford, NJ). The highest dose was selected based on 
the studies of sub-chronic toxicity and carcinogenicity of TCE in mice (National Toxicology 
Program, 1990). Mice were sacrificed 24 h after treatment, tissues were flash frozen in liquid 
nitrogen and stored at 80 C until analysis. In the highest dose group, mice from 5 CC strains died 
before sacrifice; therefore, all further analyses were conducted on 45 CC strains with complete 
dose–response data. All treatments were conducted between 8 and 11 am to limit potential diurnal 
variation in TCE metabolism. In life portion of the study was conducted over a 6-week time-frame 
to limit seasonal variations. These studies were approved by the Institutional Animal Care and Use 
Committees at Texas A&M University and the University of North Carolina. 
TCA levels in tissues. Analyses were performed by a modification of US EPA method 552.2 
(Domino, Pepich, Munch, Fair, & Xie, 2003).(Domino, Pepich, Munch, Fair, & Xie, 2003) In 
brief, 50 mg of kidney, 100 mg of liver, 50 mg of brain, or 100 µL of serum was homogenized in 
1 mL chloroform: methanol (1:1) containing 20 µL of 2-bromobutyric acid (550 nmol/mL). 
Distilled deionized water (300 µL) was added to the homogenate followed by vortexing and 
centrifugation at 15 000 rpm for 10 min. The supernatant was transferred to a new vial containing 
1.5 mL of 10% sulfuric acid in methanol and incubated in a water bath at 50 C for 2 h. Methyl 
esters were extracted in 2 mL methyl tert-butyl ether followed by addition of 3 mL sodium sulfate 
(100 g/L). . The organic layer was neutralized by addition of 3 mL saturated sodium bicarbonate 
solution and concentrated under a stream of nitrogen gas to a volume <50 µL. A calibration curve 
from 0 to 1000 nmol/g consisting of TCA spiked into tissues before extraction was run with each 
batch for quantitative analysis. The extracts were analyzed using a HP 6890 gas chromatography 
system coupled with a HP 5973 mass selective detector (Agilent Technologies, Santa Clara, CA). 
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A 2 µL sample was introduced into gas chromatograph by splitless injection on to a 30 m x 0.25 
mm, 0.25 mm HP5-ms column (Agilent Technologies). The carrier gas flow was set at a constant 
flow rate of 1 mL/min. The oven was held isothermally at 40 C for 10 min and then ramped to 65 
C over the next 10 min, then to 85 C for the next 2 min, and finally to 205 C over 6 min. The 
injector and transfer line temperatures were maintained at 210 C and 280 C, respectively. The mass 
selective detector operated in the electron impact mode with the ion source set at 230 C and 
electron energy at 70 eV. Methyl esters of TCA and 2-bromobutyric acid were quantified by 
monitoring the ion at 59 m/z. Ions at m/z 117, 119, 151, and 153 were used to identify the analytes.  
Extraction of hepatic microsomes and cytosolic fractions. A published protocol was 
adapted for the extraction of microsomal and cytosolic fractions (Yan and Caldwell, 2004). In 
brief, 100 mg of liver tissue was homogenized in 1 mL ice-cold 50 mM tris base solution 
containing 15 mM potassium chloride and centrifuged at 9000 g for 20 min. The supernatant was 
transferred to a new vial and ultra-centrifuged at 100,000 g for 1 h at 4C. The supernatant was 
aliquoted and the microsomal pellet was re-suspended in 200 µL 50 mM tris-HCl (with 20% 
glycerol, pH 7.4) and stored at 80 C. Total protein concentration was measured using a Pierce BCA 
Protein Assay Kit (ThermoFisher Scientific, Waltham, MA). 
Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) activity assays. 
ADH and ALDH activity assay kits were purchased from Sigma-Aldrich. Activity assays were 
performed on cytosolic extracts according to the manufacturer’s protocol. 
CYP1A1 activity assay. Magnesium chloride, glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, resorufin, resorufin ethyl ether, and b-nicotinamide adenine dinucleotide 
phosphate hydrate reduced tetra sodium salt hydrate (NADPH) were purchased from Sigma-
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Aldrich. Microsomal incubations were setup according to a published protocol (Yan and Caldwell, 
2004). In brief, 100 µL of chilled tris base buffer, 50 µL of 5 mM MgCl2, 50 µL of 5 mM glucose-
6-phosphate, 50 µL of 0.5 mM NADPH, 250 mg of microsomal protein, and 10 µL of 3.3 mM 
resorufin ethyl ether were incubated in a 96-well plate. Formation of resorufin was monitored at 
excitation and emission wavelengths of 530 nm and 585 nm, respectively. A standard curve from 
0 to 1 mM for resorufin was generated using heat-inactivated microsomes. 
CYP2E1 protein expression. About 20–30 mg pulverized liver tissue was homogenized in 
400 µL tissue protein extraction reagent (T-PER, ThermoFisher Scientific) containing HALT 
protease inhibitor cocktail (ThermoFisher Scientific). The homogenate was centrifuged at 10,000 
g for 5 min and the proteins in the supernatant were transferred to a new vial. The isolated proteins 
were quantified using Pierce BCA Protein Assay Kit (ThermoFisher Scientific). Protein aliquots 
(20 mg) were loaded on to an SDS-PAGE containing of Mini-Protean TGX precast gels (Bio-Rad, 
Richmond, CA). Western blotting was performed using Trans-blot Turbo Transfer System (Bio-
Rad), and Immuno-Blot PVDF membranes (Bio-Rad). Membranes were blocked using Odyssey 
blocking buffer (Li-Cor, Lincoln, NE) and were incubated overnight at 4 C with 1:5000 anti-
CYP2E1 antibody (Abcam, Cambridge, MA). The membranes were then washed and incubated 
with 1:2500 goat anti-rabbit antibody conjugated with peroxidase (Millipore, Bedford, MA). 
Protein bands were developed by chemiluminescent staining with WesternSure ECL Substrate 
visualized by C-Digit Blot-Scanner (Li-Cor). Anti-b-actin antibody (1:2500, Abcam) staining was 
used as a loading control.  
Gene expression analysis by RT-PCR. Total RNA was isolated from 20 to 30 mg of 
pulverized left liver lobes in liquid nitrogen using MiRNeasy mini kit (Qiagen, Valencia, CA). 
RNA concentrations were measured using Nanodrop ND-1000 (Thermo Fisher Scientific). cDNA 
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was synthesized from 2 µg RNA using High Capacity cDNA Achieve kit (Thermo Fisher 
Scientific). Quantitative real-time PCR was performed using Taqman probes for genes Acox1, 
Acot8, Cyp4a10, Cd40, Fitm2, and Top1 (Abcam) on Light Cycler 96 (Roche, Indianapolis, IN). 
Genome-wide quantitative trait locus (QTL) mapping. High-density sequences of CC genomes 
for strains used in this study were downloaded from the UNC Systems Genetic Core (http: //csbio. 
unc.edu/CCstatus/index.py?run¼Pseudo; last accessed March 31, 2017). Information on reference 
SNPs for genes were acquired from the Mouse Genome Informatics database (http:// 
www.informatics.jax.org/; last accessed March 31, 2017). Flanking DNA sequences for each SNP 
in each CC strain was performed using a custom R script. QTL mapping was performed using 
DOQTL package (D. M. Gatti et al., 2014) using a model that considered each of the eight founder 
alleles separately. Only seven founder alleles were present in the mapping population at the 
location Acox1 QTL, resulting in overfitting of DOQTL’s eight-allele model. In order to better 
estimate the QTL effects, we simulated CC mapping populations that consisted of our actual CC 
lines plus an additional three simulated lines that harbored the PWK allele missing form our 
mapping population. We assigned each simulated line a phenotype randomly sampled the observed 
phenotype distribution (such that the simulated lines would not affect the QTL) and remapped in 
the QTL region. These simulations yielded a properly fitted model and improved estimates of the 
effects of the other seven alleles. 
Statistical analysis. Graph Pad Prism (La Jolla, CA) was used to perform statistical tests. R 
(v.3.1.2) was used to generate line graphs and boxplots (ggplot2). For all tests, a P < .05 was 
required for statistical significance. In analyses that involved multiple comparisons, a false 
discover-corrected q values were derived. Data availability. All raw data are publically-available 
through the Mouse Phenome Database (http://phenome.jax.org/; ID: Rusyn8). 
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III. Results 
Mouse Population Variability in Metabolism of TCE to TCA. Metabolism is critical for the 
toxicity, mutagenicity, and carcinogenicity of TCE; TCA is the most abundant metabolite that is 
formed through cytochrome P450 (CYP)-dependent oxidation [Figure 2.1, reviewed in (Cichocki 
et al., 2016; Lash et al., 2014). Because of the focus on the dose–response effects of TCE and 
toxicodynamic responses among multi-tissues, a single time point of 24 h was selected. At this 
time point, only TCA is detectable in mouse tissues at comparable highest doses (S. Kim et al., 
2009). We observed extensive strain-dependent variability in TCA levels in mouse tissues (liver, 
kidney, brain, and serum) 24 h after oral dosing with TCE (Figure 2.2, Supplementary Figures 
1.1A–1.1C). At each dose (24–800 mg/kg), the capacity to metabolize TCE via the oxidative 
pathway varied by an order of magnitude or more among strains. Appreciable consistency exists 
among strains with high, intermediate, or low TCA levels across all dose groups (Supplementary 
Figure 2.1). For example, strains CC028/GeniUnc, CC059/TauUNC, and CC010/GeniUnc showed 
relatively high levels of TCA in liver across different dose groups (Figure 2.2). Similarly, strains 
CC042/GeniUnc, CC017/Unc, and CC055/TauUnc are low responders, and strains 
CC006/TauUnc, CC030/GeniUnc, and CC003/Unc show intermediate levels of TCA at 24 h after 
dosing. We observed similar trends in kidney, brain and serum (Supplementary Figures 2.1–2.3). 
Next, we compared the population-level (using data from 45 CC strains) variability in TCA 
amounts at 24 h in liver, kidney, brain, and serum with that predicted by a population-wide 
physiologically based pharmacokinetic (PBPK) model (Chiu et al., 2014a) that was calibrated with 
data from 15 classical inbred strains (Bradford et al., 2011). Figure 2.3 shows data from each strain 
(circles) compared with the PBPK model predictions (boxes). Liver TCA levels at doses of 24, 80, 
and 240 mg/kg for more than 85% of CC strains fall within the 95% confidence interval of the 
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PBPK model predictions (Figure 2.3A). Interestingly, liver TCA levels in the 800 mg/kg dose 
group are higher than the predicted 95% confidence interval for more than half of CC strains 
(Figure 2.3A). Kidney TCA levels at 24 mg/kg and 80 mg/kg doses were below the limit of 
detection for most of the CC strains; at the 240 mg/kg dose, TCA levels fall within the 95% 
confidence interval for more than 85% of CC strains (Figure 2.3B). In 800 mg/kg dose group, 
about one third of the strains fall outside of the 95% confidence interval for model-predicted 
kidney TCA levels (Figure 2.3B). Similarly, while serum TCA levels at 24 and 80 mg/kg were 
generally within the 95% confidence limit of the model, close to half of the strains are greater than 
this confidence interval in 240 and 800 mg/kg dose groups (Figure 2.3C). The most striking feature 
is the difference in predicted and observed medians, nearly every CC animal is above the median 
value predicted by the model. Overall, these results from a much larger population-based study of 
TCE toxicokinetics show that the PBPK model is under-predicting the levels of TCA in different 
tissues, especially at the highest doses. 
 
Induction of Enzyme Levels/Activity in Response to TCE Treatment. 
Oxidative metabolism of TCE to TCA is thought to involve a number of cytochrome P450 
and other enzymes (Lash et al., 2014); therefore, we sought to examine effects of TCE exposure 
on several key enzymes. Specifically, because of the observed wide range of liver TCA levels 
among strains, we sought to examine whether basal or TCE-induced levels of major microsomal 
and cytosolic enzymes involved in TCE metabolism might explain the inter-strain variability in 
liver TCA levels. Liver Cyp2e1 protein levels (Figs. 2.4A-2.4B) and liver Cyp1a1 activity (Figs. 
2.4C–2.4D) varied extensively among strains in both vehicle- and TCE (800 mg/kg) treated 
29 
 
animals. No difference of the group means was observed in response to TCE for either of these 
enzymes, albeit the variance in these parameters increased in TCE-treated group. This observation 
is concordant with a previous report that treatment with TCE was without effect on protein levels 
of liver Cyp2e1 across seven inbred strains (Yoo, Bradford, Kosyk, Uehara, et al., 2015). 
Alcohol dehydrogenases (ADH) and aldehyde dehydrogenases (ALDH) also play a key 
role in determining the metabolic flux of chloral hydrate, an intermediate metabolite that yields 
TCA (Figure 2.1). We examined activity of ADH and ALDH in livers of both vehicle- and TCE 
(800 mg/kg)-treated animals. A statistically significant increase (P < .05) in activity of both ADH 
and ALDH was observed with TCE exposure (Figure 2.5). 
Because we observed large differences in liver levels of TCA among strains, we also 
examined whether TCE-induced peroxisomal proliferation varied. While TCE and TCA are 
PPARα ligands (Maloney & Waxman, 1999; Y. C. Zhou & Waxman, 1998), it is well known that 
expression and protein levels of PPARα are not affected by TCE (Fang et al., 2013; Ramdhan et 
al., 2008) and other peroxisome proliferators (Ito et al., 2007) but its transcription factor activity 
is affected. Therefore, we examined transcript levels of two PPARα-responsive genes, cytochrome 
P450 subfamily 4 polypeptide 10 (Cyp4a10) and acyl-CoA oxidase 1 (Acox1) in livers of vehicle 
and TCE (800 mg/kg) treated animals. Both Acox1 and Cyp4a10 transcript levels were induced 
(P < .05) by TCE (Figure 2.6). Similar to our observation in a smaller population of inbred strains 
(Bradford et al., 2011) strain-specific effects were prominent. The expression of both transcripts 
was either not affected or increased in TCE-treated animals in all strains (with the exception of 
Cyp4a10 levels in strain CC037/TauUnc). The magnitude of the effects on PPARα-mediated gene 
expression was much more robust than effects on Cyp2e1, Cyp1a1, ADH, or Aldh (Figs. 2.4 and 
2.5). 
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Correlation of Enzyme Levels/Activity with TCA Liver Concentrations. 
 To further examine the relationships between TCA levels in different tissues and other 
phenotypes evaluated in this population-based mouse study, we performed correlation (Spearman 
rank) analysis using data on CC mice from the 800 mg/kg dose group (Supplementary Table 2.1). 
We observed that TCA levels correlate positively among all tissues examined, with the highest 
correlation among liver, brain and kidney (Figure 2.7A). In addition, we found that liver TCA 
levels positively correlated with induction of Acox1 transcript levels in the liver, and the 
transcriptional effects of TCE on Acox1 and Cyp4a10, both markers of activation of transcription 
factor PPARα, were also significantly correlated (Figure 2.7B). These data suggest that inter-strain 
differences in TCE metabolism may be associated with TCE-mediated responses in CC mice. 
Notably, liver levels of TCA did not correlate with either basal or TCE-affected protein levels or 
activity of Cyp2e1, Cyp1a1, ADH, or Aldh, an observation that is similar to the findings of (Yoo, 
Bradford, Kosyk, Uehara, et al., 2015).  
QTL mapping 
 To identify genomic regions associated with inter-strain differences in TCE metabolism 
and transcriptional changes, we mapped QTL using a model that considered each of the eight 
founder alleles separately using liver TCA and Acox1 transcript levels in the highest treatment 
group. We identified quantitative trait loci (QTL) on chromosome 2 for each of the phenotypes 
(Figs. 2.8A and 2.8C). Further, we observed that NOD/ShiLTJ and WSB/EiJ founder alleles have 
most pronounced effects on QTLs associated with TCA formation and Acox1 induction (Figs. 
2.8B and 2.8D).  
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There are many protein-coding genes in the locus associated with the variability in liver 
TCA levels across the population (Table 2.1). From this list, candidate genes were selected based 
on the available information for their function that could be linked to the effects of TCE. We chose 
acyl-coenzyme A thioesterase 8 (Acot8) and Fat Storage Inducing Transmembrane protein 2 
(Fitm2) as candidate genes for further analysis because of their role in PPAR signaling, as well as 
several neighboring genes not involved in PPAR signaling or metabolism, Cluster of 
Differentiation 40 (Cd40) and Topoisomerase 1 (Top1). We performed RT-PCR to further 
examine whether transcript levels of the candidate and neighboring genes are associated with the 
phenotype, level of TCA in liver, used for mapping. Induction of Acot8 and Fitm2 expression was 
significantly positively correlated with liver TCA; Cd40 and Top1 transcript levels showed no 
correlation with this phenotype (Figure 2.9). 
The QTL associated with strain-specific variability in TCE-induced liver expression of 
Acox1 (Table 1.1) contained only one protein coding gene, Low Density Lipoprotein Receptor-
Related Protein 1B (Lrp1b). Even though, Lrp1b is a tumor suppressor gene regulated via the 
PPARγ signaling pathways (Liu, Musco, Lisitsina, Yaklichkin, & Lisitsyn, 2000), it was neither 
expressed in livers of the mice included in this study, nor was it induced by TCE. 
To further explore the role of PPARα signaling in the variability associated with TCE 
metabolism, we considered the potential contribution from the genetic variants of PPARα. There 
are two non-synonymous coding SNPs (rs16820391 and rs16820392) in PPARα in the CC founder 
strains. The frequency of distribution of A/G missense substitution for both SNPs was around 50% 
across CC strains included in this study. No statistically significant difference was observed in 
liver TCA levels among strains with PPARα genotypes (A/G) for either SNP (data not shown). It 
is well established that retinoid X receptor alpha (RXRα), a type II nuclear receptor is capable of 
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interacting with PPARα and PPARγ by forming heterodimers thereby mediating fatty acid and 
lipid metabolism (Berger & Moller, 2002; Chandra et al., 2008). A nonsynonymous SNP 
(rs16817900) generating a C/T missense substitution was identified among the CC founder strains 
and was also present in 4 out of 45 CC strains examined. Interestingly, we found that in strains 
with RXRα C genotype, liver TCA levels were about 2-fold lower (in both mean and median) than 
in T allele strains (Supplementary Figure 2.4). Although, no statistical significant difference was 
observed between C/T genotypes and liver TCA levels because only 4 strains harbor the C allele 
this finding suggests PPAR-RXR signaling as contributing to differences in oxidative metabolism 
of TCE among CC strains. 
IV. Discussion 
The focus of this study was on characterizing the extent of population-level variability in 
chemically mediated responses in a diverse population, as well as on exploring the mechanisms of 
such variability using genetic mapping. Although several previous studies used classical inbred 
strains to assess inter-individual variability in TCE metabolism and toxicity, they were limited in 
the degree of genetic diversity. In the CC mouse population, genetic variants are randomly 
distributed across the genome, creating a mosaic genome with potentially significant differences 
in cellular functions as compared with those in the founder strains. Consequently, the CC lines 
permit high-resolution QTL mapping, enabling the identification of the genes that may be 
associated with the phenotypic variability at the genome level. 
Using a CC mouse population, we aimed to increase precision of the estimates for the extent 
of inter-individual variability in TCE metabolism. Data from this study was compared with a 
previous study (Bradford et al., 2011) where a multi-strain panel was used to assess variability in 
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TCE metabolism. In the Bradford et al. (2011) study, inter-strain differences in the TCA levels in 
serum at 24 h post-dosing at 2,100 mg/kg TCE were around 4- to 6-fold across strains. In CC 
population, we observed more than an order of magnitude differences in the level of TCA at 24 h 
in tissues (using 800 mg/kg TCE dose data), further supporting the importance of genetic 
variability in TCE metabolism. We also found that select strains are low, intermediate or high 
“metabolizers” of TCE to TCA. To determine the concordance in population-level variability 
among two population-based studies, median estimates of TCA levels were derived using a PBPK 
model (Chiu et al., 2014a) and compared with the data in this study. We found that inter-strain 
variability in TCA levels in the CC mice was concordant with PBPK model predictions at lower 
doses across tissues. However, at the 800 mg/kg dose, nearly half of all strains were above the 
predicted ranges across different tissues. Metabolism of TCE in the rat is a saturable process at 
doses around 1,000 mg/kg, but in the mouse TCE metabolism is linear up to a dose of 2,000 mg/kg 
(Prout, Provan, & Green, 1985). Thus, our results are unlikely to be due to metabolic saturation 
and suggest that genetic diversity among CC mice may play a role in inter-strain differences in 
TCE toxicokinetics. The fact that model-derived median predictions were about one half to an 
order of magnitude below the observed values across all tissues examined is an indication that our 
data may be useful for updating the model with a larger population and data from additional tissues. 
In addition, further exploration of strain-dependent variability in concentration–time responses is 
needed. One additional test for the hypothesis that genetic diversity plays a role in inter-strain 
differences in toxicokinetics would be selection of strains representing population-level variability 
in TCA levels for a toxicokinetic study that will evaluate TCE metabolite levels at concentration–
time across various tissues. 
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Several enzymes are involved in the oxidative metabolism of TCE to TCA (Lash et al., 2000). 
Genes associated with CYP, ADH, and ALDH families are known to be polymorphic and to result 
in inter-individual differences in their activity among individuals (Pastino, Yap, & Carroquino, 
2000). Little evidence for the inter-individual differences in TCE metabolism through oxidation 
exist in human populations or in experimental animal studies. Most studies examined the role of 
polymorphisms in CYP2E1 and ADH/ALDH pathway, genes that are known not only to be 
polymorphic, but also contain polymorphisms that have known linkages to human cancer 
susceptibility (Li, Zhao, Sun, Luo, & Xiao, 2016). CYP2E1 is the principal enzyme responsible 
for metabolism of TCE in humans and rodents (Pastino et al., 2000). Other CYP isoforms including 
CYP1A1 have also been associated with TCE metabolism. We observed little difference in 
CYP2E1 and CYP1A1 activity levels in both TCE- and vehicle-treated mice. Yoo et al. (2015a) 
reported suggestive, but only marginally significant (P ¼ .06) correlation between liver TCA and 
basal CYP2E1 protein levels in a panel of 7 mouse inbred strains that are parental strains for CC. 
In the present study, we did not find a correlation between TCA and basal CYP2E1 protein levels 
in liver suggesting that a more complex milieu of oxidative enzymes may be responsible for TCE 
metabolism to TCA.  
Interestingly, 10-fold or greater inter-strain differences were observed in ADH and ALDH 
activities in both vehicle- and TCE-treated animals. We also observed significant increases in 
ALDH and ADH activity with TCE exposure. Further, the extent of variability in these enzymes 
across mouse strains was consistent with previously reported variability in ALDH and ADH 
activity in human cryopreserved hepatocytes (Bronley-DeLancey et al., 2006). However, no 
association was observed between TCA levels and activity of ADH or ALDH, again suggesting 
that multiple factors may be responsible for the observed differences in TCA levels. We also 
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observed no correlations between TCE-metabolizing enzyme levels or activity, indicating lack of 
potential additive interactions among these enzymes in certain strains. Thus, while mouse 
population-derived data demonstrate the utility of the CC mouse population in capturing the 
population-level variability observed in humans, they also show the complexities of the oxidative 
metabolism of TCE whereby multiple enzymes play a role in TCE toxicokinetics. 
TCA and other products of oxidative metabolism of TCE are well known to be PPARα agonists 
and peroxisome proliferation is one mechanism of liver toxicity and carcinogenesis of TCE (Bull 
et al., 1990; Rusyn et al., 2014). In our study, we hypothesized that strains with higher TCA levels 
would exhibit greater effects on PPARα-mediated signaling. Indeed, we observed significant 
induction and positive correlation in the transcription of PPARα-responsive Acox1 and Cyp4a10 
genes with TCE treatment, with levels of Acox1 transcripts and TCA levels in liver also positively 
correlated. This is an important finding as it demonstrates the association between TCE 
metabolism and toxicodynamics. It also confirms the findings reported in Bradford et al. (2011) 
that peroxisome proliferator activated receptor-mediated molecular networks, consisting of the 
metabolism genes known to be induced by TCE, represent some of the most pronounced molecular 
effects of TCE treatment in mouse liver that are dependent on genetic background. These results 
are also consistent with findings that Acox1 and Cyp4a10 transcript levels are induced with 
repeated exposure to TCE and are positively correlated with each other and with liver TCA levels 
(Yoo, Bradford, Kosyk, Uehara, et al., 2015).  
While a strong and reproducible concordance between liver TCA levels and induction of 
peroxisome proliferation at a population level confirms the traditional sequence of events: 
metabolism of TCE to TCA which then acts as a PPARα ligand and induces peroxisomal 
proliferation, the outcome of the haplotype-associated mapping afforded by CC population 
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suggests that a feedback loop also exists. A novel outcome of this study is the identification of 
candidate genes at QTLs associated with TCE metabolism to TCA. Among several protein-coding 
genes in the locus significantly associated with liver TCA levels among strains, Acot8 and Fitm2 
were identified as candidate genes and were significantly correlated with TCA levels. These results 
are intriguing as Acot8 and Fitm2 are PPAR-responsive genes, suggesting the role of PPAR 
signaling in TCE metabolism, in addition to the role of TCE metabolites in peroxisome 
proliferation. A recent study showed significantly lower levels of TCA in the liver and kidney in 
PPARα-null and -humanized mice after either single or repeated exposures to TCE, suggesting a 
direct role of PPARα signaling in TCE toxicokinetics (Yoo, Cichocki, et al., 2015). 
Another indication that genetic variants associated with PPARα signaling are associated with 
TCE metabolism to TCA is the observation that strains carrying a non-synonymous SNP variant 
(C genotype) in RXRα are associated with relatively low levels of TCA. PPARs are nuclear 
receptors that require dimerization with the nuclear receptor RXRα to form a heterodimer. The C 
genotype of RXRα is carried in the CAST/Eij strain among the CC founders. Although, no 
statistically significant differences in TCA levels were observed between C and T genotypes of 
RXRα, strains with C genotype demonstrated 2-fold lower mean and median TCA levels compared 
with strains carrying the T genotype. Results of previous studies also suggest that the CAST-
specific alleles may be a significant contributor to the variability associated with TCE metabolism. 
(Yoo, Bradford, Kosyk, et al., 2015a; Yoo, Bradford, Kosyk, Uehara, et al., 2015) found that TCA 
levels in serum, liver and kidneys after exposure to TCE were the lowest in CAST/Eij strain as 
compared with other CC parental strains. A similar observation was reported by Bradford et al. 
(2011) in a comparison of 15 mouse inbred strains. Despite differences in dose and study designs, 
consistently low TCA levels in CAST/Eij strains across studies are highly reproducible, supporting 
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the suggestion that genetic variants in RXRα and other genes may contribute to the observed inter-
strain variability in TCE metabolism.  
This study, while informative with respect to quantitation and discovery of the genetic drivers 
of inter-individual variability, has a number of limitations. First, while we surveyed a dose–
response in a large population of CC strains, we did not examine intra-strain reproducibility. In 
order to maximize the power of the study design with respect to mapping, we maximized the 
number of strains, not replicates (Kaeppler, 1997). Consistency of dose–response curves within 
each strain and concordance of major effects and relationships among the phenotypes with other 
multi-strain studies suggests that strain-specific effects are reproducible; however, this needs to be 
tested in subsequent studies. Studies also need to examine toxicokinetics of TCE in a 
concentration–time study design. Second, this study examined only a single time point and a more 
complete understanding of the effects that inter-strain differences in TCE metabolism may have 
on the apical toxicity phenotypes is needed though sub-chronic and chronic studies. Our data on 
strain-specific metabolism of TCE will be crucial for selection of strains for follow up longer term 
studies because it is unlikely that such studies can be done in a comparably large mouse population. 
While highly informative, population-based studies are challenging in terms of cost and logistics; 
thus, acute treatment-based surveys in large populations will likely be a very useful approach for 
narrowing the number of strains while preserving the extend of population variability through data-
driven study designs and strain selection. 
In summary, our results show that the CC mouse population is a valuable tool for assessing 
inter-individual variability and for investigating the genetic basis of the phenotypic differences. 
The mosaic genomes of CC enabled identification of the candidate genes underlying differences 
in TCE metabolism and support a role for PPAR signaling not only in TCE toxicity, but also in 
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TCE metabolism. This observation further supports the need for caution suggested by (Yoo, 
Cichocki, et al., 2015) in interpreting apparent species differences in PPAR signaling, because they 
may result from not only receptor-mediated toxicodynamic effects, but also modulation of 
toxicokinetics. Consequently, these results suggest the need to investigate interplay between 
varying genetic backgrounds and interspecies differences, and thereby improve the ability of 
experiment studies to predict risks to human populations. 
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V. Figures and Tables 
Figure 2.1. Schematic representation of metabolism of trichloroethylene (TCE) via oxidative 
pathway. Names of metabolites that are chemically unstable or reactive are shown in brackets. 
Major enzymatic pathways are identified for cytochrome P450 enzymes (CYPs), aldehyde 
dehydrogenase (ALDH), alcohol dehydrogenase (ADH), UDP-glucuronosyltransferase (UGT), 
and GSH S-transferase zeta (GSTZ). 
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Figure 2.2. Liver TCA levels in CC mice 24 h after oral administration of a dose of 24 (A), 80 (B), 
240 (C), or 800 (D) mg/kg of TCE. Bars colored in red, green, and blue represent strains that 
exhibit high, intermediate and low, respectively, levels of TCA across different treatment groups. 
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Figure 2.3. Inter-strain variability in formation of TCA in liver (A), kidney (B), and serum (C) 24 
h after oral administration of a dose of 24, 80, 240, or 800 mg/kg of TCE. Each dot represents 
TCA level in a CC strain, horizontal black line indicates median value for each dose-tissue 
combination among CC strains. Red box and whiskers are PBPK model-derived (Chiu et al., 2014) 
population estimates. The boxes and the horizontal line represent 5, 95, and 50% median TCA 
levels. The whiskers represent upper and lower bound confidence interval for 95 and 5%, 
respectively, median TCA levels. 
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Figure 2.4. Inter-strain differences in liver Cyp2e1 protein expression (A–B) and Cyp1a1 activity 
(C–D) in CC mice administered vehicle (black circles) or a single oral dose of TCE (800 mg/kg, 
red circles). Panels (B) and (D) are box and whiskers plots of population variability where a 
horizontal line represents the median, the box shows 1st and 3rd quartile ranges and the whiskers 
represent standard errors of the mean. 
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Figure 2.5. Inter-strain differences in liver ADH (A–B) and ALDH (C–D) activity in CC mice 
administered vehicle (black circles) or a single oral dose of TCE (800 mg/kg, red circles). Panels 
(B) and (D) are box and whiskers plots of population variability where a horizontal line represents 
the median, the box shows 1st and 3rd quartile ranges and the whiskers represent standard errors 
of the mean. The asterisks (*) denote statistical significant differences (P < .05) between TCE and 
vehicle treated groups (Mann–Whitney test). 
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Figure 2.6. Inter-strain differences in liver Acox1 (A–B) and Cyp4a10 (C–D) transcript levels in 
CC mice administered vehicle (black circles) or a single oral dose of TCE (800 mg/kg, red circles). 
Panels (B) and (D) are box and whiskers plots of population variability where a horizontal line 
represents the median, the box shows 1st and 3rd quartile ranges and the whiskers represent 
standard errors of the mean. The asterisks (*) denote statistical significant differences (P < .05) 
between TCE and vehicle treated groups (Mann–Whitney test). 
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Figure 2.7. Correlation analysis (Spearman) among toxicokinetic and toxicodynamic phenotypes 
across the population of CC strains. A, Scatter plots of TCA levels at 24 h after dosing with 800 
mg/kg of TCE in multiple tissues of 45 CC strains. Trend lines and corresponding r and P-values 
are shown. B, Correlation between expression of Acox1, Cyp4a10, and liver TCA levels in 
responses to TCE treatment. Full correlation matrix is included as Supplementary Table 1. 
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Figure 2.8. QTL mapping of TCE toxicokinetic and toxicodynamic phenotypes. Log transformed 
liver TCA (A–B) and Acox1 (C–D) transcript levels measured at 24-h time point in CC mice 
administered with a single oral dose of TCE (800 mg/kg) were mapped to the mouse genome 
polymorphisms among CC strains. Panels A and C show logarithmic odds ratio (LOD) scores 
across the whole mouse genome (chromosomes 1 through X). The red line represents a 
permutation-based significance threshold (n ¼ 1000 permutations). Plots B and D show the effect 
of the CC founder strain alleles on chromosome 2 (top) and a zoom-in on the significant regions 
with corresponding LOD scores. 
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Figure 2.9. QTL region on distal chromosome 2 associated with liver TCA levels. RefSeq genes 
that are located on chr2 [qH2-qH3] in the region between 160,640,000 and 165,200,000 (a sub-set 
of the entire QTL, see Table 1) are shown with a position marked for the candidate genes 
(abbreviation, full name and physical genomic location are shown) that were examined for the 
relationship between TCE-induced expression and TCA level in livers of CC mice treated with a 
single oral dose of 800 mg/kg of TCE. Scatter plots show correlation among gene expression for 
Top1, Fitm2, Acot8, and Cd40 and liver TCA levels. Best fit linear regression lines are plotted and 
corresponding r and P values are depicted on each plot. 
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Table 2.1 Significant quantitative trait loci and genes in these loci that were associated with inter-
strain differences in Liver TCA and TCE-Induced Induction in Acox1 Expression in Liver 
Phenotype Genomic 
position 
(Mb) 
Protein coding genes in the locus 
TCA Chr 2: 
157.685-
180.142 Mb 
CTNNBL1, VSTM2L, TTI1, RPRD1B, TGM2, BPI, LBP, SNHG11, 
RALGAPB, ADIG, ARHGAP40, SLC32A1, ACTR5, PPP1R16B, 
FAM83D, DHX35, MAFB, TOP1, PLCG1, ZHX3, LPIN3, EMILIN3, 
CHD6, PTPRT, CISD3B, SRSF6, L3MBTL1, SGK2, IFT52, MYBL2, 
GTSF1L, TOX2, JPH2, OSER1, GDAP1L1, FITM2, R3HDML, 
HNF4A, TTPAL, SERINC3, PKIG, ADA, WISP2, KCNK15, RIMS4, 
YWHAB, PABPC1L, TOMM34, STK4, KCNS1, WFDC5, WFDC12, 
WFDC15A, WFDC15B, SVS2, SVS3B, SVS4, SVS3A, SVS6, SVS5, 
SLPI, MATN4, RBPJL, SDC4, SYS1, TRP53TG5, DBNDD2, PIGT, 
WFDC2, SPINT3, WFDC6A, EPPIN, WFDC8, WFDC6B, WFDC16, 
WFDC9, WFDC10, WFDC11, WFDC13, SPINT4, SPINT5, WFDC3, 
DNTTIP1, UBE2C, TNNC2, SNX21, ACOT8, ZSWIM3, ZSWIM1, 
SPATA25, NEURL2, CTSA, PLTP, PCIF1, ZFP335, MMP9, SLC12A5, 
NCOA5, CD40, CDH22, SLC35C2, ELMO2, ZFP663, ZFP334, 
OCSTAMP, SLC13A3, TRP53RKA, SLC2A10, EYA2, ZMYND8, 
NCOA3, SULF2, PREX1, TRP53RKB, ARFGEF2, CSE1L, STAU1, 
DDX27, ZNFX1, KCNB1, PTGIS, B4GALT5, SLC9A8, SPATA2, 
RNF114, SNAI1, UBE2V1, TMEM189, CEBPB, PTPN1, FAM65C, 
PARD6B, ADNP, DPM1, MOCS3, KCNG1, NFATC2, ATP9A, SALL4, 
ZFP64, TSHZ2, ZFP217, BCAS1, CYP24A1, PFDN4, DOK5, CBLN4, 
MC3R, FAM210B, AURKA, CSTF1, CASS4, RTFDC1, GCNT7, 
FAM209, TFAP2C, BMP7, SPO11, RAE1, RBM38, CTCFL, PCK1, 
ZBP1, PMEPA1, ANKRD60, RAB22A, VAPB, STX16, NPEPL1, 
NELFCD, CTSZ, TUBB1, ATP5E, SLMO2, ZFP831, EDN3, ETOHI1, 
ZFP931, PHACTR3, SYCP2, PPP1R3D, FAM217B, CDH26, CDH4, 
TAF4, LSM14B, PSMA7, SS18L1, MTG2, HRH3, OSBPL2 
Acox1 
induction by 
TCE in liver 
Chr 2: 
41.836-
43.374 Mb 
LRP1B 
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Supplemental Figure 2.1. Dose-response plots of liver, kidney, serum and brain TCA levels in CC 
mice 24 h after oral administration of TCE (24-800 mg/kg).  Lines colored in red, green, and blue 
represent strains that exhibit high, intermediate and low levels of TCA across different treatment 
groups. Dotted lines represent other strains. Lines connect values across doses from a strain. 
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Supplemental Figure 2.2. Serum TCA levels in CC mice 24 h after oral administration of a dose 
of 80 (A), 240 (B), or 800 (C) mg/kg of TCE.  Bars colored in red, green, and blue represent strains 
that exhibit high, intermediate and low levels of TCA across different treatment groups. The order 
of strains is in accordance with rank ordering of strains for liver TCA (800 mg/kg TCE). 
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Supplemental Figure 2.3. Kidney (A-B) and brain (C-D) TCA levels in CC mice 24 h after oral 
administration of a dose of 240 or 800 mg/kg of TCE.  Bars colored in red, green, and blue represent strains 
that exhibit high, intermediate and low levels of TCA across different treatment groups. The order of strains 
is in accordance with rank ordering of strains for liver TCA (800 mg/kg TCE). 
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Supplemental Figure 2.4. Liver TCA levels in RXR variants among CC mice orally administered with 
800 mg/kg of TCE. The box shows 1st and 3rd quartile ranges and the whiskers represent standard error of 
the mean. 
 
 
 
 
Supplemental Table 2.1. P-values (uncorrected) for Spearman correlation among phenotypes collected in this study (Top). 
Bonferroni-corrected p-values for Spearman correlation among phenotypes collected in this study (bottom). 
                              ADH_TCE ADH_veh ALDH_TCE ALDH_Veh Cyp1a1_TCE Cyp1a1_Veh Cyp2e1_TCE Cyp2e1_Veh Cyp4a10 Acox1 TCA 
ADH_TCE 1 0.4429 0.9729 0.3232 0.9988 0.4138 0.3736 0.2598 0.9422 0.8715 0.7074 
ADH_veh 0.4429 1 0.0289 0.2457 0.5914 0.9747 0.123 0.2243 0.6074 0.0901 0.0962 
ALDH_TCE 0.9729 0.0289 1 0.0061 0.1959 0.5327 0.1998 0.0479 0.1249 0.9928 0.5551 
ALDH_Veh 0.3232 0.2457 0.0061 1 0.6935 0.5704 0.1606 0.0453 0.2583 0.6617 0.0402 
Cyp1a1_TCE 0.9988 0.5914 0.1959 0.6935 1 0.0873 0.8918 0.2455 0.7692 0.9928 0.5289 
Cyp1a1_Veh 0.4138 0.9747 0.5327 0.5704 0.0873 1 0.5159 0.9002 0.4147 0.7959 0.3158 
Cyp2e1_TCE 0.3736 0.123 0.1998 0.1606 0.8918 0.5159 1 0.5542 0.7901 0.2392 0.0977 
Cyp2e1_Veh 0.2598 0.2243 0.0479 0.0453 0.2455 0.9002 0.5542 1 0.0737 0.2126 0.8656 
Cyp4a10 0.9422 0.6074 0.1249 0.2583 0.7692 0.4147 0.7901 0.0737 1 0.0023 0.0588 
Acox1 0.8715 0.0901 0.9928 0.6617 0.9928 0.7959 0.2392 0.2126 0.0023 1 0.0002 
TCA 0.7074 0.0962 0.5551 0.0402 0.5289 0.3158 0.0977 0.8656 0.0558 0.0002 1 
    
 ADH_TCE ADH_veh ALDH_TCE ALDH_Veh Cyp1a1_TCE Cyp1a1_Veh Cyp2e1_TCE Cyp2e1_Veh Cyp4a10 Acox1 TCA 
ADH_TCE 1 1 1 1 1 1 1 1 1 1 1 
ADH_veh 1 1 0.289 1 1 1 1 1 1 0.901 0.962 
ALDH_TCE 1 0.289 1 0.061 1 1 1 0.479 1 1 1 
ALDH_Veh 1 1 0.061 1 1 1 1 0.453 1 1 0.402 
Cyp1a1_TCE 1 1 1 1 1 0.873 1 1 1 1 1 
Cyp1a1_Veh 1 1 1 1 0.873 1 1 1 1 1 1 
Cyp2e1_TCE 1 1 1 1 1 1 1 1 1 1 0.977 
Cyp2e1_Veh 1 1 0.479 0.453 1 1 1 1 0.737 1 1 
Cyp4a10 1 1 1 1 1 1 1 0.737 1 0.023 0.588 
Acox1 1 0.901 1 1 1 1 1 1 0.023 1 0.002 
TCA 1 0.962 1 0.402 1 1 0.977 1 0.558 0.002 1 
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CHAPTER 3: CHARACTERIZATION OF GENETIC BACKGROUND, DOSE, AND 
THEIR COMBINATORY EFFECTS ON LIVER GENE EXPRESSION RESPONSES 
WITH TCE EXPOSURE2 
I. Introduction 
Gene expression profiling is widely used in the field of toxicology and provides important 
molecular insights into the mechanisms of adverse health effects from chemical exposure 
(Burczynski et al., 2000; Harrill & Rusyn, 2008). Transcriptomic signatures of chemical exposures 
have been widely used in chemical safety evaluation and large reference databases exist to enable 
comparative analyses and predictive modeling (Fostel, 2008; Ganter et al., 2005; Uehara et al., 
2010). In addition, many studies demonstrate the value of transcriptomic data-derived dose-
response information for both hazard identification and quantitative risk assessment (Andersen et 
al., 2008; Thomas, Philbert, et al., 2013a) and pathway-based dose-response analysis of 
transcriptomic data displayed concordance with traditional apical endpoints (Thomas et al., 2007b; 
Thomas et al., 2011; Thomas, Philbert, et al., 2013a; Y. H. Zhou et al., 2017). Indeed, 
toxicogenomics data are making their way into decision making for both drugs and environmental 
chemicals (Sauer et al., 2017; J. Xu, Thakkar, Gong, & Tong, 2016). 
The majority of available gene expression data in toxicology has been collected in genetically 
homogenous (e.g., a single strain or cell line) or undefined (e.g., outbred strains or mixtures of 
                                                          
2 The text of this chapter is reproduced with permission from Mammalian Genome 29 (1-2): 168-181 (2018). 
Springer Nature © 2018  
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cells from multiple individuals) model systems. However, it is well established that gene 
expression, both basal and disease/treatment-perturbed, is heavily impacted by genetic variation 
among individuals (Bradford et al., 2011; Bystrykh et al., 2005; Chesler et al., 2003; D. Gatti et 
al., 2007; Harrill, Ross, Gatti, Threadgill, & Rusyn, 2009; Schadt et al., 2008; Schadt et al., 2003). 
Early studies of expression quantitative trait loci (eQTL) were conducted in panels of inbred mouse 
strains or human cell lines where population stratification was a challenge (D. M. Gatti, Harrill, 
Wright, Threadgill, & Rusyn, 2009) and recent studies in more heterogeneous mouse models such 
as Diversity Outbred (DO) and Collaborative Cross (CC) show greater promise of characterizing 
and replicating eQTLs (Crowley et al., 2015). 
Studies of chemical effects using population-based models, both in vivo and in vitro, are 
increasingly common (Abdo, Xia, et al., 2015; Church et al., 2015; Cichocki et al., 2017; Eduati 
et al., 2015; French et al., 2015; Luo, Furuya, Chiu, & Rusyn, 2018; Mosedale et al., 2017; 
Venkatratnam et al., 2017). Powered by the balanced genetic diversity represented in the DO 
(Churchill et al., 2012) and CC (Threadgill, Miller, Churchill, & de Villena, 2011) populations, 
these mouse models enable exploration of causal variants driving variability in molecular 
mechanisms that result in phenotypic differences (Harrill & McAllister, 2017). Furthermore, 
characterization of the genetics-dependent and -independent transcriptional responses to chemical 
exposure is valuable for elucidating the extent and mechanisms of variability (Church et al., 2015; 
Harrill, Ross, et al., 2009; Mosedale et al., 2017). 
The ensuing challenge in toxicology and environmental health is combining the 
mechanistic power of gene expression and genetics studies of chemical exposures with the need 
to understand the dose-response relationships. The complexity and cost of population-based 
studies that include multiple doses and parallel characterization of multiple dimensions of 
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toxicokinetics, toxicodynamics and inter-individual variability present unique challenges and may 
be best addressed using case studies of well-characterized toxicants (Rusyn, Gatti, Wiltshire, 
Kleeberger, & Threadgill, 2010). Thus, we chose trichloroethylene (TCE), a ubiquitous 
contaminant and a known carcinogen in both humans and rodents (Rusyn et al., 2014). TCE is a 
chemical with known variability in toxicokinetics (Chiu et al., 2014a) and toxicodynamics 
(Bradford et al., 2011). The objective of this study was to evaluate and characterize genetic 
background-, dose- and interaction-effects of TCE on liver gene expression, and to determine 
variability in dose-pathway relationships in a large genetically-diverse mouse population. Liver 
transcriptomic data from 50 strains of CC mice that were treated acutely with one of four doses of 
TCE were modeled to identify genes and pathways that exhibited significant strain, dose, or strain 
by dose interaction effects. 
II. Materials and methods 
Animals and Treatments. The in life portion of the study and tissue collection was detailed 
in (Venkatratnam et al., 2017). In brief, adult male mice (8-12 weeks old) from 50 CC strains were 
orally administered a single dose of 0, 24, 80, 240 or 800 mg/kg TCE (Sigma Aldrich, St. Louis, 
MO) in 5% Alkamuls EL-620 vehicle (Solvay, Deptford, NJ). Mice were sacrificed 24 h after 
treatment and tissues were flash frozen in liquid nitrogen and stored at -80oC until analysis.  
TCA level in liver. Analyses were performed by a modification of US EPA method 552.2 
(Domino et al., 2003) as detailed in (Venkatratnam et al., 2017). Data on TCA levels in liver across 
all CC strains was reported in (Domino et al., 2003)(Venkatratnam et al., 2017). 
RNA extraction and sequencing. Left-lobe of livers was pulverized with pestle and mortar 
pre-chilled in liquid nitrogen. RNA was extracted from ~20 mg of pulverized tissue using RNeasy 
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Qiagen mini Kit (Qiagen, Valencia, CA). Concentration of extracted RNA was measured using 
NanoDrop 2000 (Thermo Fisher Scientific, Wilmington, DE). RNA libraries were prepared using 
Illumina TruSeq Stranded Total RNA kit (Illumina, San Diego, CA) with Ribo-Zero Gold rRNA 
removal kit (Illumina). RNA-Seq of 50 base-pair single-end reads was conducted using Illumina 
HiSeq 2500 instrument (Illumina) at the depth of ~50 million reads/sample. Raw reads were 
trimmed for any sequencing adaptors and low quality bases using Trimmomatic (Bolger, Lohse, 
& Usadel, 2014). Reference genomes and inferred marker founder origin for CC mice were 
downloaded from University of North Carolina Systems Genetics Core Facility 
(http://csbio.unc.edu/CCstatus/index.py?run=Pseudo). Filtered reads were mapped to each of the 
corresponding CC reference genome using TopHat version 2.0.3 (D. Kim, Langmead, & Salzberg, 
2015). Resulting alignments were re-mapped to reference mm10 assembly coordinates using lapels 
(https://github.com/shunping/lapels). HTSeq (Anders, Pyl, & Huber, 2015) was used to generate 
raw read counts per gene using intersection-nonempty parameter to account for ambiguous read 
mappings. Differential gene expression tests were then performed with DESeq2 (Love, Huber, & 
Anders, 2014).  
Statistical analyses. Normalized count data on 23,948 genes for 246 combinations for four 
TCE and one vehicle treatments from CC strains was generated with R (version 3.3) package 
DESeq2 as detailed above. Genes with < 2 counts across all treatments were removed, leaving 
19,870 genes for analysis. The “dose” vector was linearized by first replacing the vehicle (i.e., 
zero) TCE dose with 8 (the average distance between doses was 1/3 the prior dose) followed by a 
natural log transformation. DESeq2 was used to derive p-values and adjusted p-values for the main 
effects of dose and strain, as well as their interaction. In brief, counts were first modeled as: counts 
~ strain + ln(dose). Genes exhibiting a linear dose effect were identified with a likelihood ratio test 
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comparing a reduced model of counts ~ strain. Similarly, genes exhibiting a strain effect were 
identified with a likelihood ratio test comparing a reduced model of counts ~ ln(dose) to the full 
model. Lastly, genes with an interaction effect were identified comparing a reduced model of 
counts ~ strain + ln(dose) to a full model of counts ~ strain + ln(dose) + strain*ln(dose). In a similar 
fashion, these analyses were repeated using the natural log of measured liver TCA metabolite 
concentration in nmol/g (with a +1 offset to guard against taking logarithm of zero) as a predictor 
instead of TCE dose.  Differential expression gene results were subjected to multiple comparison 
adjustment by computing Benjamini-Hochberg false-discovery q-values as implement in DESeq2. 
Due to the large number of significant findings, stringent significance criteria (q<0.001) and 
absolute counts (read counts > 10) were used as criteria for further analysis.  
Pathway analyses. Pathway enrichment analysis was conducted using The Database for 
Annotation, Visualization, and Integrated Discovery (DAVID) (Dennis et al., 2003). The top 3000 
or fewer genes with Bonferroni corrected p values (q < 0.001) were uploaded to DAVID to identify 
pathways influenced by dose-, strain-, or interaction-effects. 
Comparison of Transcriptomic Benchmark Doses with Apical Data.  For dose-response 
expression studies, the BMDExpress software (Yang, Allen, & Thomas, 2007) has been  used to 
evaluate benchmark doses for expression changes of individual genes with exposure. Although the 
current study has a large sample size, the sample size of 5 per strain presents a challenge in 
computing strain-specific benchmark doses, and in fact many of the models provided in 
BMDExpress would suffer from extreme overfitting with such small sample sizes. To best accord 
with our differential expression analyses and to benefit from the variance shrinkage models used 
in expression analyses, we devised the following approach to compute a strain-specific pathway 
BMD analogue.  First, we used the strain-specific linear modeling routine from DESeq2 as 
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described to obtain slope (?̂?1) and intercept (?̂?0) estimates from the software’s modeling of 
logarithmic gene expression, as well as the Wald-like t-statistic (which utilizes variance shrinkage 
estimation).  Next, an artificial model standard deviation ?̂? was computed from the model in order 
to be consistent with the reported p-value. Specifically, if t* represents the shrunken t-statistic, 
?̂? =
?̂?1
𝑡∗
√∑ (𝑥𝑖 − ?̅?)2𝑖  for x=ln (dose). Finally, we have the per-gene BMD=ln (control dose) 
+𝑠𝑖𝑔𝑛(?̂?1) ?̂?/?̂?1. The final BMD reflects the point at which the dose-response fit is estimated to 
exhibit a 1 standard-deviation departure from control expression, using shrunken estimates of 
variation that are obtained from the DESeq2 modeling. To compute a pathway (gene set) BMD, 
we used the median BMD of all genes assigned to the pathway.  
Previous studies have suggested that transcriptomic points of departure (PODs) correlated 
with those for apical endpoints, and that therefore transcriptional BMD values have the potential 
to serve as POD for quantitative risk assessment (Thomas et al., 2011).  We therefore compared 
transcriptomic BMDs with apical BMDLs used for liver effects in the U.S. EPA’s Toxicological 
Review for TCE (U.S. EPA, 2011a, 2011b). Specifically, U.S. EPA selected increased liver/body 
weight ratio BMDLs in mice and rats for liver non-cancer effects, and increased carcinomas in 
mice for liver cancer. Because apical endpoint PODs were derived from both rats and mice, each 
with differing toxicokinetics, we standardized all dose units to human equivalent doses (HEDs) 
based on equivalent liver oxidative metabolism, using the most up-to-date multi-species 
physiologically-based pharmacokinetic (PBPK) model (Chiu & Ginsberg, 2011; Chiu, Okino, & 
Evans, 2009).  Median estimates of each internal dose metric from Chiu et al. (2009) were used.  
An additional reason for this standardization is that margins of exposure can be readily computed 
and compared based on the human equivalent dose.  Apical endpoint HEDs were then compared 
to median transcriptional BMDL values.   
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Genetic mapping and eQTL analyses: In principle, mapping of traits in CC lines can be 
performed by analysis of variance, using for each locus the ancestral origin from each of the 8 
founding CC lines as a categorical predictor. In practice, for many loci slight uncertainties of CC 
line origin remain, due to incomplete information on crossover events in the CC breeding 
outcomes. Hidden Markov modeling enables probabilistic statements of the parental line of origins 
for each locus, expressed as probabilities (summing to 1.0) for the eight founder lines. For the vast 
majority of loci and CC lines, a very large probability (greater than 0.95) is placed on the most 
likely parental origin for the locus.  We performed regression modeling using trait as a response, 
and the probability vector as a predictor for a model with 8 degrees of freedom.  Each trait, whether 
a phenotype such as TCE dose or TCA level, or an expression trait, was first transformed using 
rank-inverse normal transformation (GTEx Consortium, 2015) to ensure robustness to outliers. 
eQTL analysis was performed separately for each dosage group using the R package DOQTL1, 
and results were compared to direct likelihood ratios computed using regression F-statistics as 
described below to ensure correct computation. Expression traits were used only if they had both 
a mean number of reads ≥5 and a nonzero read proportion of at least 10%. 
To accord with standard linkage mapping, the log10 likelihood ratio (LOD score) for the 
fitted model vs. the null was used to represent mapping evidence. At each locus, a p-value can be 
obtained from LOD scores via chi-square testing and standard likelihood ratio theory. However, 
initial investigation by permutation showed that p-values based on normal theory regression F-
statistics were superior, i.e. were more nearly uniform under the null, and so were used for multiple 
comparisons as described below. 
To facilitate multiple comparisons and to acknowledge that cis-eQTLs are more common 
than trans-eQTLs, we obtained separate cis- and trans- p-values for each expression trait as 
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follows. First, 1000 permutations of a normally-distributed “phenotype” were performed, and the 
linkage F-statistics computed across the genome. As the rank-inverse normal transformation 
produces identical transformed values for any trait (provided there are no ties), the permutations 
formed a generic set of sampling outcomes that are applicable to any quantitative trait. For each 
permutation, the maximum F-statistic was recorded for each chromosome. Thus, for each 
chromosome we obtained a set of 1000 maxima on the chromosome (cis) and 1000 maxima on the 
remaining chromosomes (trans). For each of these 40 sets of permutations (20 chromosomes, both 
cis and trans), the maximum F-statistic was modeled via maximum likelihood fitting to a Gompertz 
extreme value distribution, providing the basis for cis- and trans- p-values for each expression trait.  
By construction, these p-values control for multiple comparisons across different loci. In order to 
control for multiple comparisons across different genes, each of the sets of cis p-values and trans 
p-values were adjusted using the qvalue package in R, resulting in false discovery q-values for 
both cis and trans. For non-expression traits such as TCA levels, the overall maximum F-statistic 
distribution was used in the extreme value modeling to obtain a genome-wide p-value. 
III. Results 
Dose-, strain- and interaction-related effects of TCE on liver gene expression 
Previous studies of inter-strain variability of TCE effects demonstrated that liver 
transcriptomic responses are strongly dependent on genetic background and that peroxisome 
proliferator-activated receptor-associated pathways represented some of the most pronounced 
genetic-background dependent molecular effects of TCE treatment in mouse liver (Bradford et al., 
2011). Although this earlier study provided greater understanding of the mechanisms of TCE-
induced toxicity anchored on genotype-phenotype correlations, it included only 15 inbred strains 
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and did not examine dose-response relationships. In an effort to further elucidate how TCE 
responses differ by genetic background- and dose-expression relationships, we utilized liver gene 
expression data from 50 CC strains and 4 dose groups (plus vehicle).  
Dose, strain, and interaction effects were modeled for each transcript for both TCE dose and liver 
levels of TCA in each mouse. Exemplar plots of genes that were significant for one or several of 
these relationships are displayed in Figure 3.1, panel A shows the dose-response relationships for 
the administered dose of TCE and panel B for a correlation with liver TCA level in each individual 
mouse. For example, we observed that expression of UDP-glucuronosyltransferase family 2 
member A3 (Ugt2a3) was down-regulated with TCE dose, but this effect on gene expression was 
strain independent, with no dose by strain interaction effect. The effects of TCE on UDP-
glucuronosyltransferase enzymes is not well characterized, but it is known that glucuronidation of 
trichloroethanol, a major oxidative metabolite of TCE, is a detoxification mechanism (Chiu, 
Micallef, Monster, & Bois, 2007). Baseline expression levels of alcohol dehydrogenase 1 (Adh1) 
varied dramatically by strain but did not exhibit a significant dose-response to TCE or a dose by 
strain effect. Alcohol dehydrogenases are involved in the biotransformation of TCE metabolites 
chloral and chloral hydrate to trichloroethanol (Lash et al., 2014) and our finding of a high degree 
of inter-individual variability is consistent with previous observations in both humans and mice 
(Bronley-DeLancey et al., 2006; Venkatratnam et al., 2017). In contrast to the Ugt2a3 and Adh1 
examples, the expression of acyl-CoA thioesterase 7 (Acot7) exhibited not only a strong baseline 
strain effect, but also a strain by dose interaction effect. Acot7 is a PPAR-responsive gene 
(Rakhshandehroo, Knoch, Muller, & Kersten, 2010). Indeed, PPAR-signaling plays a critical 
role in the effects of TCE in rodent liver (Rusyn et al., 2014). Of note, all three example genes 
depicted in Figure 3.1 exhibited highly significant dose, strain and interaction effects regardless 
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whether TCE dose, or liver TCA concentrations were used as the “dose”, demonstrating that at 
least for these exemplars, that TCA plays a key role in transcriptional responses to TCE in mouse 
liver, likely through its agonism to PPAR (Maloney & Waxman, 1999). 
Overall, we found that 5,285 transcripts were significant (after multiple testing correction 
as described) for the effect of TCE dose, 11,820 for the effect of strain, and 2,140 for the interaction 
between the two (Figure 3.2, left column of Venn diagrams). When liver TCA was used as an input 
into the model, 4,769 transcripts were significant for TCA, 13,920 for strain, and 2,242 for 
interaction (Figure 3.2, right column). Interestingly, a very small number of transcripts was purely 
dose-dependent, without an effect of strain or interaction, only less than 1% of the transcriptome. 
In contrast, the effect of strain on the transcriptome was a major factor, representing in excess of 
the 50% of all transcripts that were mapped. This observation is consistent with the dominant effect 
of genetic variability on transcription in the liver (D. Gatti et al., 2007; Schadt et al., 2008), and 
general findings on the impact of genetic variation in expression regulation (GTEx Consortium, 
2013, 2015).  
Whether analyzing the effects of TCE dose on expression in liver, or the relationship 
between liver TCA concentration and liver expression, we found significant overlap in expression 
signatures. This finding is not completely unexpected, as there is strong correlation (r=0.78, 
p=0.86) between TCE dose and liver TCA levels (Figure 3.3A). However, this  observation points 
to the important, but not exclusive, role of TCA as the “effector” metabolite of TCE in rodent liver 
which is largely realized through transcriptional and other downstream effects. The importance of 
including the dose-response considerations in the analysis of the population-wide transcriptional 
response to toxicity is illustrated in Figure 3.3B. While there is a significant positive correlation 
(r=0.49, p<0.001) between the number of significantly perturbed transcripts and liver TCA at the 
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highest TCE dose level, this relationship is highly strain-variable whereby many strains with the 
highest liver TCA were not the most “responsive” transcriptionally. 
Dose-, strain- and interaction-related effects of TCE on liver pathways 
Next, we examined the molecular pathways perturbed by TCE in mouse liver in a dose-, 
strain-, or interaction-dependent manner. To examine concordance in pathways between TCE dose 
and liver TCA, significant Gene Ontology and KEGG pathways/category enrichment was 
examined using DAVID/EASE (q-value<0.001), for lists of transcripts with significant dose 
(Figure 3.3C), strain (Figure 3.3D), or interaction (Figure 3.3E) effects. Most pathways for the 
dose and strain effects were shared between TCE dose and liver TCA analyses (marked in green), 
and their level of significance was highly concordant (slopes close to 1).   
Due to the high degree of concordance, we show the pathway results for TCE dose for 
using DAVID/EASE (Tables 3.1 and 3.2). Pathways from significant dose-related transcripts are 
shown in Table 1. Pathways with strong TCE dose-response relationships included lipid and fatty 
acid metabolism. Most of these were also significant for the strain effect and they are closely 
related to PPAR signaling, a finding consistent with our understanding of the major molecular 
effects of TCE in the rodent liver (Rusyn et al., 2014). Another prominent group of dose-responsive 
pathways was the effect on cell-cell adhesion and gap junctional intercellular communication, also 
consistent with previous findings that exposure to TCE and TCA inhibits gap junctional 
communications in mouse hepatocytes (Klaunig, Ruch, & Lin, 1989).  
While there was a greater number of genes that exhibited strain-specific changes in gene 
expression, enrichment analysis yielded fewer discernable significantly enriched pathways (Table 
3.2). Two translation-related pathways were significant for strain alone and not dose or interaction. 
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Pathways that were both strain- and dose-dependent were largely similar to those in Table 3.1, 
showing that the large part of TCE dose-response response is highly dependent on the genetic 
background. 
Comparison of PODs for transcriptional and apical effects of TCE in mouse liver 
Next we sought to compare transcriptomics-derived dose-response effects of TCE in this 
acute exposure study in genetically diverse CC mice to the traditional apical endpoint-derived 
PODs for the same tissue but in other animal models. Specifically, we based these comparisons on 
the effects of TCE on liver transcriptome in B6C3F1 strain (Y. H. Zhou et al., 2017) and the liver 
non-cancer and cancer endpoints used by U.S. EPA to derive toxicity values (U.S. EPA, 2011a, 
2011b).  For this comparison, we converted both types of PODs to human equivalent doses using 
a multi-species PBPK models, as described in Methods, and the results are shown in Figure 3.4A.  
Because of the lack of PBPK models specifically for CC mice, we used the median estimates for 
mice from the PBPK model, which was calibrated using data from Swiss and B6C3F1 mice (Chiu 
et al., 2014a; M. V. Evans, Chiu, Okino, & Caldwell, 2009). The transcriptional PODs covered the 
same range of human equivalent doses as the apical endpoints, with the most sensitive median 
BMDL (KEGG_mmu00071, fatty acid degradation) being nearly the same as the most sensitive 
apical endpoint-derived BMDL (B6C3F1 mouse liver carcinomas).  Overall, the median 
transcriptional BMDLs across all pathways in CC mice were within 10-fold of the apical PODs 
for TCE effects in the liver. 
A corollary of this analysis is a question of whether data from the CC population are more 
informative as compared to the analysis of the dose-response gene and pathway effects of TCE in 
B6C3F1 hybrid strain. Thus, we constructed strain-specific distributions using the data for the 
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same pathways (Figure 3.4B). We find that B6C3F1 strain-derived data fall into the upper tertile 
of the overall population variability distribution, above the apical data-derived PODs.  
Furthermore, the analysis of strain-specific effects of TCE on mouse liver transcriptome that is 
afforded by the CC population shows that certain strains are more sensitive (e.g., CC004/TauUnc) 
or resistant (e.g., CC039/Unc, CC023/GeniUnc and CC018/Unc) and may be selected for further 
studies in sub-chronic and chronic exposure scenarios.  Interestingly, although the most sensitive 
strain CC004/TauUnc had transcriptional PODs that were 10-fold lower than those of B6C3F1 
mice, the median transcriptional POD for this strain was within 2-fold of the most sensitive apical 
POD. 
Genetic mapping of the transcriptional effects of TCE in mouse liver  
To further elucidate whether the CC model provides sufficient resolution to dissect the 
genetic underpinnings of TCE susceptibility, we conducted genome-wide linkage mapping to 
identify loci associated with variability in liver TCA levels for the highest TCE dose group. As 
reported previously (Venkatratnam et al., 2017), we identified a significant QTL on distal 
chromosome 2 (Figure 3.5A) associated with variability in liver TCA levels, although the robust 
mapping methods used here differ from the previous report. The previous study also reported that 
expression of PPARα-response gene Fitm2 (Fat Storage Inducing Transmembrane Protein-2) 
which resides in this locus (red arrowhead) was positively correlated with liver TCA levels for the 
highest TCE dose exposure group. 
In the current study, the availability of whole-transcriptomic expression data enabled a 
more comprehensive examination of this locus for the potential association between genetic 
polymorphisms and gene expression. A linkage scan for expression of Fitm2 co-localized with the 
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TCA peak region (Figure 3.5B) and indicates a strong eQTL. Among the genes in a 1.5-LOD 
support interval for this locus, Fitm2 had the highest correlation with TCA levels (Figure 3.5C).  
Further, effects of CC founder alleles in this region revealed that  presence of M.m.castaneous 
alleles in this region is associated with higher expression of Fitm2 (Figure 3.5C). However, TCA 
levels and Fitm2 expression were substantially correlated within sets of CC strains sharing regional 
diplotypes, indicating possible additional sources of positive correlation and signaling potential 
additional complexities with confidently pointing to the genetic underpinnings of inter-individual 
variability in liver TCA levels.  
To conduct a more comprehensive analysis of the genetic underpinnings of variation in 
response to TCE, we additionally performed an analysis using, for each gene and CC strain, the 
slope of the expression response (β1 in a dose-response linear model) to TCE as a trait for linkage 
mapping. To be comprehensive, we performed the analysis using β1 values from both simple linear 
regression of expression vs. ln(dose), as well as β1 values from the DESeq2 analyses. Separate cis 
and trans p-values and corresponding false discovery q-values were obtained as described in 
Methods.  In terms of q-values (which are corrected for multiple comparisons), none of the results 
were significant.  
Finally, to identify genetic loci driving variability in transcriptomic responses, we 
performed expression quantitative trait locus (eQTL) analysis at each dose group. We observed 
trans-bands (or instances where expression of several genes are driven by a common locus) in 
chromosomes 3, 11, and 12 in the vehicle treatment group. No trans-bands were observed at lower 
dose groups, but few trans-bands were observed at higher dose groups (data not shown). Figure 
3.5D reports the numbers of significant local (cis) eQTLs at each dose group in a Venn diagram, 
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illustrating variation by dose, but also considerable commonality, with 2285 genes significant at 
q<0.05 for all doses. 
IV. Discussion 
It is widely acknowledged in the fields of toxicology and risk assessment that population 
variability is one of the key challenges that begets uncertainty in human health assessments of 
environmental chemicals (Zeise et al., 2013). Drug safety evaluation is usually more informed 
through studies in humans at various phases of the clinical trials, still the challenge of idiosyncratic 
adverse drug reactions is also prominent and subject to active investigations (Atienzar et al., 2016). 
Solutions to these challenges are currently few, despite the abundance of experimental models 
from cells, to animals, to human studies. For instance, the tools for studies of genetics in 
experimental model systems have been originally developed by geneticists (Churchill et al., 2012; 
The International HapMap Consortium, 2003; Threadgill et al., 2011) and only fairly recently these 
models have been used in studies of acute and repeat-dose exposure to drugs and chemicals 
(French et al., 2015; Harrill & McAllister, 2017). The potential for how these new animal models 
can inform risk assessment is great, though example applications of incorporating these data into 
decision-making remain small in number (Chiu & Rusyn, 2018). For instance, evaluation of 
toxicity using population-based in vitro and in vivo models can potentially reduce both false 
positive and false negative signals and improve hazard identification. Enhanced ability to perform 
genetic mapping allows for the identification of key biological pathways and mechanisms that may 
be involved in toxicity and/or susceptibility.  In addition, population-based toxicity data can serve 
as a surrogate for human variability, and thus be used to quantitatively estimate the degree of 
human toxicokinetic/toxicodynamic variability and thereby increase confidence in the dose-
response step of risk assessment that sets health-protective exposure limits. 
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The difficulty in translating the data from studies in population-based experimental models to 
real decisions is due not only to the complexities of the relationships between genotypes and 
phenotypes, but also because of impediments resulting from “cultural” differences between the 
research questions in genetics, decades-old “standard practices” in toxicology studies, and the 
needs of decision-makers. Specifically, there appears to be a chasm in what constitutes the most 
valuable outcome(s) of a toxicology study in a population model. Is it a susceptibly locus, the 
molecular determinant(s) of inter-individual variability that may be used as a biomarker, a 
quantitative estimate of the extent of inter-individual variability, a better “model” (i.e., strain or 
cell line) for susceptible humans, or all of the above. 
This study takes the “all of the above” point of view. It adds to the body of knowledge on 
the utility of the mouse population-based experimental models in toxicology and risk assessment 
by examining transcriptomic data obtained from a study in CC mice for characterization of strain-
dependent and -independent mechanisms of TCE toxicity, discovery of the potential susceptibility 
loci, as well as dose-response assessment and derivation of POD values. This study provides 
further evidence of the relative impact of dose and strain variation on transcription, and is among 
the largest studies to date that have combined large populations, transcriptomics and toxicity 
phenotyping.   
We found that all known pathways of liver toxicity of TCE (Cichocki et al., 2016; Rusyn 
et al., 2014) are perturbed in both strain- and dose-dependent manner. Even though strain effects 
were predominant in terms of liver transcriptome among CC strains, TCE effects were prominent 
and largely dependent on the formation of TCA. However, despite high concordance in dose-, 
strain- and interaction-effects between TCE dose and liver TCA levels, the inter-individual 
variability likely depends on factors other than metabolism to TCA. This finding is highly 
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informative with respect to not only the interpretation of the strain differences in the mouse, but 
also the extrapolation of these data to humans. The diversity of the pathways involved and the 
complexity of the signaling mechanisms that were largely strain-dependent caution against over-
reliance on studies in knockout and/or transgenic animals as more informative, or human-like, 
models. This study also supports the utility of the information on the molecular pathways, rather 
than individual genes, for cross-species translation and biomarker discovery, similar to the 
conclusions of the study of tolvaptan-induced liver injury in CC population (Mosedale et al., 2017). 
Additionally, studies in genetically defined population-wide models enable discovery of the 
susceptibility loci through genetic mapping. There are a number of published examples where 
susceptibility loci and candidate genes were successfully identified for drug and chemical-
associated toxicity phenotypes (French et al., 2015; Harrill, Watkins, et al., 2009; Mosedale et al., 
2017; Venkatratnam et al., 2017). Despite some success, these studies have pointed out that 
chemical-induced toxicities are highly complex traits and thus are polygenic in nature. Our study 
confirms this sentiment by also exploring the gene expression dimension. We found that TCE-
mediated transcriptional responses in mouse liver may be highly polygenic in nature, so that 
mapping multiple susceptibility loci may be difficult with the sample size of 50 CC strains. One 
possible solution is to increase the number of strains (Kaeppler, 1997), or replicates per strain in 
future studies; however, the cost and complexity of these studies is likely prohibitive and not 
proportionate to the value of information that may be obtained. While the knowledge of the exact 
susceptibility genes/loci may be of use for drugs in the context of “precision medicine,” even if 
such are discovered they are likely to be less informative in the context of human health assessment 
of TCE and other chemicals for which genetic testing prior to exposure is highly improbable. 
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An outcome of this study that is most likely to be of use for human health risk assessment is 
the exploration of dose-response relationships in response to TCE at the transcriptomic and 
population levels. The seminal paper by French and co-workers (French et al., 2015) was the first 
to demonstrate the value of mouse population studies for quantitative dose-response modeling that 
is directly applicable for risk assessment. Similarly, we have shown previously for TCE that 
population-based estimates of toxicokinetic parameters from a study in mice are concordant to 
those for data from humans (Chiu et al., 2014a). Hence, our study explored the quantitative aspects 
of molecular sequelae of exposure to TCE in a mouse population and used gene expression to 
derive PODs for various pathways and strains. Thomas and coworkers have demonstrated that 
pathway-based POD based on gene expression data from short-term exposure studies are well 
correlated with the POD on the apical endpoints derived from traditional 90 day and 2 year animal 
studies (Farmahin et al., 2017; Thomas et al., 2011; Thomas, Wesselkamper, et al., 2013). 
We recently reported that in B6C3F1 mice, transcriptional PODs for TCE correlated well 
with PODs for apical endpoints, after correcting for toxicokinetics (Zhou et al. 2017). Here, we 
found a similar correspondence to apical endpoint PODs using transcriptomic data from a 
genetically diverse mouse population.  Previously, it was found that the transcriptional POD were 
more conservative, generally within one order of magnitude (Thomas et al., 2011).  In our earlier 
study in B6C3F1 mice, transcriptional PODs for TCE were also within 10-fold of apical PODs, 
but the differences were in both directions, i.e. not consistently conservative. Here, in CC mice, 
the transcriptional and apical endpoint PODs for TCE substantially overlapped, a large number of 
transcriptional pathways, including the most sensitive falling within the range of the apical 
endpoint PODs.  This greater apparent correlation suggests that using CC mice may provide a 
more robust transcriptional POD because of the incorporation of genetic diversity that reduces the 
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potential impact of outliers, but this hypothesis needs to be tested for additional chemicals and 
target tissues.  Moreover, as was the case with Zhou et al. (2017), conversion to human equivalent 
doses has the additional utility of being directly comparable to human exposure estimates and 
derivation of the margins of exposure.  These results provide further evidence that transcriptomic 
data can be used as surrogates for in vivo PODs, and suggest that a population-based approach 
might be more robust than using a single strain. 
 In summary, our study is among the first to explore the linkages between gene expression 
and genetic polymorphisms in a toxicological context.  This innovative approach extends the 
common method to analyzing toxicity pathway perturbations to the population level, allowing for 
an exploration of gene-environment interactions, which are thought to be the basis of phenotypic 
variation across the population.  Using the CC population and TCE liver effects as a prototypical 
example, we have demonstrated that adding the dimension of genetic diversity has multiple 
potential benefits.  First, by identifying pathways that are dependent on strain, treatment, or their 
interaction, we obtain deeper insights into toxicological mechanisms. Second, it enables the 
possibility of genetic mapping to identify susceptibility loci, although this may be challenging for 
polygenic traits such as TCE-induced liver effects.  Finally, at least in this case, conducting gene 
expression dose-response analysis across a population appears to be more robust than using a 
single strain in terms of the correlation between transcriptional and apical PODs. Overall, our study 
demonstrates the utility of mouse population-based studies in addressing the key issue of inter-
individual variability in the human health risk assessment of chemical exposures.   
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V. Figures and Tables 
Figure 3.1. Examples of genes (Ugt2a3, Adh1, and Acot7) that were affected by exposure to 
TCE in mouse liver in genetic background-, dose- or interaction-dependent manner. Top panel (A) 
shows correlation with administered TCE dose; bottom panel (B) is correlation with liver TCA 
levels at 24 hrs after dosing.  Each circle represents gene expression in a CC mouse. Each line 
represents a linear dose-response fit for each CC strain. The y-axis represents normalized counts 
of the expression. The x-axis in the top panel represents administered TCE dose (mg/kg) and in 
the bottom panel represents liver TCA levels (nmol/g) in the CC population.  False discovery q-
values (q≤0.001) for dose and strain main effects, as well as their interaction, are displayed in each 
box. 
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Figure 3.2. Venn diagrams representing total number of transcripts from the transcriptome that are 
strongly influenced by genetic background-, dose-, or interaction-effects with administered TCE 
dose (left panel) or liver TCA (right panel) as dose inputs. Numbers within each sector of circles 
represents either unique or common transcripts. Percentages represent the total percent of 
transcripts from the liver transcriptome that are common between TCE dose and TCA level 
analyses. 
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Figure 3.3. Concordance between TCE dose and liver TCA levels based on gene- and pathway-
based analyses. (A) Scatter-plot showing individual animal’s liver TCA (nmol/g) as compared to 
the administered TCE dose (mg/kg). The inset shows the results of the correlation analysis of these 
data. (B) A relationship between liver TCA levels and the number of significantly (q<0.05) 
perturbed transcripts by the TCE (800 mg/kg) in each CC strain. The inset shows the results of the 
correlation analysis of these data. (C) Concordance in pathways that were significantly (q<0.01) 
associated with dose (top), strain (middle), or interaction (bottom) for the analyses where TCE 
dose (x-axis) or liver TCA (y-axis) were used as dose inputs. Each dot is a KEGG or GO 
pathway/category. Pathways that were significant only for TCE are colored black, only for liver 
TCA are colored red and pathways that were significant for both are colored green. 
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Figure 3.4. Comparison of point of departures (PODs) across significantly (q<0.001) perturbed 
pathways due to genetic background-, dose-, and interaction-effects in the CC model with apical 
endpoints from sub-chronic or chronic TCE studies in B6C3F1. Box plots represent PODs, 
converted to human equivalent dose (mg/kg-d) using mouse and human physiologically-based 
pharmacokinetic models, for the following: apical endpoints (black); transcriptional PODs for 
B6C3F1 mice from Zhou et al. (2017) (green); transcriptional PODs for CC mice aggregated 
across pathways and strains (blue, panel A only); transcriptional PODs for individual pathways, 
aggregated across CC strains (red, panel A); or transcriptional PODs for individual CC strains, 
aggregated across pathways (red, panel B). See Supplemental Table 6 for full listing of 
abbreviations used. 
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Figure 3.5. (A) A genome-wide linkage scan for liver TCA levels at the highest TCE dose (800 
mg/kg) in 50 CC lines identifies a significant QTL on chromosome 2. Location of a candidate gene 
Fitm2 is marked with a red arrowhead. (B) Genome-wide linkage scan of Fitm2 gene expression 
shows a cis-eQTL localizing in the same region as for (A). (C) Scatter plot representing liver TCA 
(nmol/g) levels versus normalized Fitm2 expression, with dots representing CC founder alleles in 
the peak region. (D) Venn diagrams displaying unique local eQTLs by administered TCE dose.  
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Table 3.1. Pathways that are significantly associated with dose-, dose-/interaction-effects, and dose 
/strain-effects. 
Category Term Count pValue qValue* 
Pathways from genes that were significantly (q<0.001) correlated with TCE dose&  
KEGG_PATHWAY mmu04146:Peroxisome 42 5.96E-13 8.65E-11 
KEGG_PATHWAY mmu00071:Fatty acid degradation 27 1.46E-09 8.49E-08 
KEGG_PATHWAY mmu03050:Proteasome 29 1.72E-12 1.66E-10 
GOTERM_BP_DIRECT GO:0055088~lipid homeostasis 22 2.21E-08 1.85E-05 
KEGG_PATHWAY mmu04610:Complement and coagulation 
cascades 
33 3.03E-08 1.46E-06 
GOTERM_CC_DIRECT GO:0005913~cell-cell adherens junction 71 3.01E-05 9.95E-04 
KEGG_PATHWAY mmu00830:Retinol metabolism 33 2.16E-06 6.96E-05 
GOTERM_MF_DIRECT GO:0016740~transferase activity 293 7.95E-10 3.24E-07 
GOTERM_BP_DIRECT GO:0006637~acyl-CoA metabolic process 18 1.33E-07 9.76E-05 
KEGG_PATHWAY mmu00053:Ascorbate and aldarate 
metabolism 
15 1.38E-05 3.08E-04 
GOTERM_CC_DIRECT GO:0034364~high-density lipoprotein 
particle 
12 3.08E-05 9.79E-04 
Pathways significantly (q<0.001) perturbed with  dose effect 
GOTERM_BP_DIRECT GO:0006351~transcription, DNA-templated 50 1.19E-08 1.34E-05 
Pathways from genes that had a significant (q<0.001) dose and strain interaction effect$ 
GOTERM_MF_DIRECT GO:0016301~kinase activity 114 1.04E-07 2.32E-05 
GOTERM_MF_DIRECT GO:0098641~cadherin binding involved in 
cell-cell adhesion 
60 5.71E-08 1.49E-05 
GOTERM_BP_DIRECT GO:0006351~transcription, DNA-templated 270 9.62E-09 9.64E-06 
GOTERM_BP_DIRECT GO:0006397~mRNA processing 62 2.18E-06 9.94E-04 
Pathways from genes that were significantly (q<0.001) correlated with TCE dose that were also strain-
dependent@ 
KEGG_PATHWAY mmu03050:Proteasome 29 1.45E-12 2.09E-10 
KEGG_PATHWAY mmu04146:Peroxisome 32 1.05E-06 6.02E-05 
KEGG_PATHWAY mmu04610:Complement and coagulation 
cascades 
35 1.38E-09 1.33E-07 
KEGG_PATHWAY mmu00830:Retinol metabolism 33 1.86E-06 8.94E-05 
GOTERM_CC_DIRECT GO:0005913~cell-cell adherens junction 74 7.54E-06 2.98E-04 
GOTERM_MF_DIRECT GO:0016740~transferase activity 300 2.69E-10 1.09E-07 
KEGG_PATHWAY mmu00053:Ascorbate and aldarate 
metabolism 
15 1.28E-05 4.08E-04 
&, Full list of the significant pathways is in Supplemental Table 1 (5285 genes) 
$, Full list of the significant pathways is in Supplemental Table 2 (2140 genes) 
@, Full list of the significant pathways is in Supplemental Table 3 (5032 genes) 
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Table 3.2. Pathways that are significantly perturbed by either strain- or strain- and dose-effects. 
Category Term Count pValue qValue* 
Pathways from genes that were significantly (q<0.001) correlated with strain effect& 
GOTERM_CC_DIRECT GO:0005840~ribosome 62 8.97E-12 1.68E-09 
GOTERM_MF_DIRECT GO:0005085~guanyl-nucleotide exchange 
factor activity 
48 3.35E-08 3.05E-05 
Pathways from genes that were significantly (q<0.001) correlated with strain that were also dose-dependent@ 
GOTERM_MF_DIRECT GO:0016705~oxidoreductase activity 41 2.11E-11 1.32E-08 
GOTERM_MF_DIRECT GO:0008392~arachidonic acid epoxygenase 
activity 
26 9.61E-11 4.50E-08 
KEGG_PATHWAY mmu00830:Retinol metabolism 38 1.17E-09 6.65E-08 
GOTERM_MF_DIRECT GO:0005506~iron ion binding 61 6.92E-09 1.30E-06 
GOTERM_CC_DIRECT GO:0031090~organelle membrane 35 1.68E-08 1.24E-06 
GOTERM_MF_DIRECT GO:0070330~aromatase activity 20 2.07E-08 3.52E-06 
GOTERM_CC_DIRECT GO:0005840~ribosome 59 2.80E-10 3.10E-08 
KEGG_PATHWAY mmu05204:Chemical carcinogenesis 45 7.83E-14 2.23E-11 
GOTERM_MF_DIRECT GO:0004364~glutathione transferase activity 20 2.94E-09 6.89E-07 
KEGG_PATHWAY mmu04512:ECM-receptor interaction 31 6.44E-06 1.15E-04 
 
&, Full list of the significant pathways is in Supplemental Table 4 (5285 genes) 
@, Full list of the significant pathways is in Supplemental Table 5 (2140 genes) 
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Supplemental Table 3.5. Pathways from genes that were significantly (q<0.001) correlated with 
strain that were also dose-dependent 
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CHAPTER 4: EVALUATION OF INTER-INDIVIDUAL DIFFERENCES IN TCE 
METABOLISM AND TOXICITY IN A 90-DAY ORAL TOXICITY TESTING USING 
GENETICALLY- DIVERSE MOUSE POPULATIONS 
I. Introduction 
Toxicity testing of chemicals is often conducted on chemicals that may pose health risk to 
humans. Since the establishment of the National Toxicology Program (NTP), several standardized 
study designs and protocols have been established to assess the toxicological potential of 
chemicals. Among the different study designs to assess risk, the 90-day or pre-chronic toxicity 
studies are critical in making regulatory decisions and conducting further animal studies. Pre-
chronic studies aid in identifying hazard, target organs, similarities and differences in responses 
between species and sexes, slope of dose-response relationships, and doses for chronic studies 
(Chhabra, Huff, Schwetz, & Selkirk, 1990). Historically, such studies are often conducted in rodent 
models with fixed genetic background. Toxicology and carcinogenesis studies contracted by NTP 
utilize B6C3F1 as the preferred strain which is derived by inter-crossing C57BL/6N with 
C3H/HENmtv- strains. Selection of such a genetic background for safety testing was based on the 
notion that the use of F1 hybrids would offer better reproducibility compared to outbred stocks 
and  minimize loss of  genetic variability as seen in inbred lines (Meek, 1987). Consequently, due 
to the homogeneous background traditional toxicity models employing B6C3F1 poorly capture 
diversity in toxic responses that arise due to genetic differences as is observed in humans. 
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Advances in mouse genetics has led to the development of different population-based rodent 
models that comprise of a large panel of genetically-diverse lines of mice derived from multi-
parental crosses of classical inbred strains of mice (Churchill et al., 2004; Churchill et al., 2012; 
Threadgill & Churchill, 2012). The rationale for multi-parental breeding strategy is to randomize 
genetic variations so that all components of systems can be interrogated as allele frequencies for 
quantitative trait locus (QTL) mapping; these models are also sufficiently large to power analyses 
of modest interactions (Threadgill & Churchill, 2012). The Collaborative Cross (CC) mice are 
derived from eight genetically-diverse classical inbred strains of mice (Churchill et al., 2004; 
Threadgill, Hunter, & Williams, 2002). The CC recombinant intercrosses (RIXs) are F1 hybrids 
that offer more heterogeneity in comparison to the CC but retain the same level of reproducibility 
(Graham et al., 2015; Threadgill & Churchill, 2012). The Diversity Outbred mice are F2 crosses 
derived from CC; due to the random breeding schemes each individual DO mouse is genetically-
unique and so reproducibility poses a challenge in the DO population (Bogue et al., 2015; Churchill 
et al., 2012).  
Several reports have shown the utility of population-based rodent resources in biomedical 
applications with an emphasis on genetic analysis of complex traits (Church et al., 2015; Durrant 
et al., 2011; Rogala et al., 2014; Smallwood et al., 2014). For example, the CC model has helped 
reproduce hallmark symptoms of Ebola hemorrhagic fever that are otherwise not observed in 
existing mouse models (Rasmussen et al., 2014). More recently, studies have also shown the utility 
of these models in toxicological research on chlorinated solvents and industrial toxicants (Cichocki 
et al., 2017; French et al., 2015; Venkatratnam et al., 2017). Although the use of these population-
based rodent resources are rapidly growing in toxicology, the quantitative extent of variability in 
toxic responses in these models have not been directly compared to B6C3F1 or between the 
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different population-based models in any study. The utility of these models derives from 
identifying genetically susceptible strains based on acute or single exposure studies in a 
population, ultimately these strains may serve as an alternative to B6C3F1 in carcinogenicity 
studies. In addition, there is lack of knowledge on whether classical toxicity markers are dependent 
on genetic background, dose, or an interaction effect between genetic background and treatment. 
To address these gaps in knowledge we aimed to conduct a toxicity study involving different 
population-based rodent models and B6C3F1.  
Trichloroethylene (TCE) is a ubiquitous environmental toxicant and a known carcinogen in 
both humans and rodents (Guha et al., 2012). It has been well established that TCE metabolism 
plays a critical role in cancer and non-cancer toxicity (Lash et al., 2014). Oxidative metabolism of 
TCE has been shown to be highly driven by dose and genetic background in mice (Venkatratnam 
et al., 2017). Physiologically-based pharmacokinetic (PBPK) modeling has demonstrated 
comparable variability in TCE toxicokinetics between humans and classical inbred strains of mice 
(Chiu et al., 2014a). The objective of this study is to evaluate inter-strain variability in responses 
within and between CC, DO, CC-RIX, and B6C3F1 populations in a 90-day oral toxicity study 
with trichloroethylene (TCE) as a case study toxicant. We hypothesized that variability in TCE 
toxicokinetics and toxicodynamics within and between different populations will be larger than 
stochastic or intra-strain variability in responses in B6C3F1. This sub-chronic study was designed 
to follow closely the NTP study design and was conducted by following the Office of Economic 
Cooperation and Development (OECD) guidelines as closely as possible. Several traditional 
markers of toxicity and metabolism were examined in each of the mouse populations. We observed 
that most of these responses within the CC and CC-RIX populations were highly variable in 
comparison to the B6C3F1, with some strains showing clear susceptibility, suggesting that genetic 
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background may have a profound effect in dose-response assessments. Collectively, this study 
provides novel information on the application of population-based rodent models to address 
challenges in risk assessments pertaining to human genetic variability. 
II. Materials and Methods 
Animals and treatment. The NTP study design for pre-chronic study consists of testing 
chemicals in two species at five different doses and a control group. Each treatment group must 
have 10 animals per sex per species. Due to the inherent genetic structure of different mouse 
populations we replaced the ’10 animals per treatment’ criterion with 10 reproducible CC or CC-
RIXs strains and 10 DO mice; this approach closely reflects that of the NTP sub-chronic study 
while allowing for the incorporation of population-based rodent models. Adult male mice (8-12 
weeks) were selected for this study as previous studies have shown that metabolic capacity is 
higher in males than females (Lash et al., 2006). 10 CC strains with a known diverse TCE 
toxicokinetic and toxicodynamic profiles from Venkatratnam et al. 2017 were selected for this 
study. To evaluate intra-strain or stochastic variability 5 mice per CC strain per dose group were 
employed in this study. 10 CC-RIXs with one mouse per strain per treatment were arbitarily 
assigned for this study. CC and CC-RIX mouse populations were acquired in multiple batches 
from University of North Carolina Systems Genetics Core (Chapel Hill, NC). 60 Non-litter mate 
DO mice and B6C3F1 mice were purchased from The Jackson Laboratories (Bar Harbor, ME). 
All animals were housed individually and were allowed to acclimate to the room for at least 7 days 
prior to beginning experimentation.  Prior to the start of the experiment, mice were anesthetized 
using isoflurane for microchip tagging with MUSSIC Identification system from Avid 
Identification systems, Inc (Norco, CA). Mice were orally administered with a daily dose of 0, 24, 
40, 80, 160 or 240 mg/kg TCE (Sigma Aldrich, St. Louis, MO) in 5% Alkamuls EL-620 vehicle 
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(Solvay, Deptford, NJ) for a period of 90 weekdays. Due to the large number of mice in this study, 
animals representing each treatment group and population were split into a series of eight groups 
for daily administration of TCE or vehicle. Oral gavages were conducted between 8 am and 12 pm 
each day to minimize circadian effects on TCE metabolism. Mice were weighed each week to 
normalize dosing by weight and were housed in regular cages in a temperature-controlled (24 °C) 
room, with a 12/12-h light/dark cycle, and were allowed access to water and regular rodent diet ad 
libitum. Three days prior to necropsy, mice were fed 5-bromo-2′-deoxyuridine (BrdU) (Sigma 
Aldrich, St. Louis, MO) in drinking water (0.2 g/L) for evaluation of cell proliferation in different 
tissues. Mice were necropsied 24 h after last dosing. These studies were conducted under the 
approval of the Institutional Animal Care and Use Committees (IACUC) at Texas A & M 
University. 
Sample collection and processing. Blood from portal vein was split into two vials – 1.1 mL 
serum collection tube (Sarstedt, Germany) for serum collection, and 300 uL Microvette collection 
vial (Sarstedt, Germany) for hematological analysis.  Femur bones were clipped from vehicle- and 
TCE- (240 mg/kg) treated animals and a fresh smear was acquired on a slide for bone marrow 
histology analysis that was later conducted at the Texas A & M University Veterinary Medical 
Diagnostic Laboratory (College Station, TX). Remaining bone marrow was centrifuged and stored 
in vials at -800C. Complete blood count (CBC) profiles for all animals were acquired using 
VetScan VS2 (Abaxis, Union City, CA). Liver, kidney, bone marrow, brain, gonadal fat pad, lung, 
spleen, and tail from all animals were collected and flash frozen. Sections of left-lobe liver, kidney, 
and duodenum were placed in cassettes and formalin fixed overnight. Formalin was decanted and 
cassettes were rinsed in tap water for a period of 5 mins. The cassettes were then placed in a 
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solution of 70% ethanol and stored at 40 C for preparation of paraffin blocks at the Veterinary 
Integrative Biosciences Histology Lab (College Station, TX).  
 Kidney Injury Marker-1 (KIM-1) assay.  Mouse TIM-1/KIM-1/HAVCR Quantikine 
ELISA Kit was purchased from R & D systems (Minneapolis, MN). In brief, 10 mg of kidney 
tissue was dissolved in 1mL of calibrator diluent RD5-26 buffer (provided by the manufacturer). 
Tissues were homogenized in 2 mL tubes with stainless steel beads for 30 seconds using Bead 
Ruptor 24 Elite (Omni International, Kennesaw, GA) and centrifuged at 10,000 rpm for 5 mins. 
The supernatant was used for analysis. The remaining steps in the analysis were conducted by 
following the manufacturer’s protocol.   
Trichloroacetic acid (TCA) measurements in tissues. Analyses were performed by a 
modification of US EPA method 552.2 (Domino et al., 2003) as detailed in Venkatratnam et al. 
2017. 
Statistics. Graph Pad Prism (La Jolla, CA) was used to perform statistical tests. R (v.3.1.2) 
was used to data plots (ggplot2) and conducting statistical analyses. For all tests, a p< 0.05 was set 
as statistical significance. 
Hepatic and renal pathology examination. Hematoxylin and Eosin (H & E) stained slides 
were prepared by Veterinary Integrative Biosciences Histology Lab (College Station, 
TX). Kidneys were sectioned longitudinally and one half was routinely fixed in formalin, paraffin 
embedded, sectioned, and stained with hematoxylin and eosin (H&E). A portion of the left liver 
lobe was treated similarly. Light microscopic examination of H&E stained kidney and liver was 
performed by a board certified veterinary anatomic pathologist (AP). Only vehicle and highest 
treatment (TCE 240 mg/kg) groups were examined by the pathologist. The pathologist was blinded 
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to treatment and mouse strain information. The entirety of the kidney and liver sections on each 
slide were examined and scored for histologic lesions on an ascending numerical semi-quantitative 
scale as described by the National Toxicology Program where 1 = minimal and 4 = marked with 
levels 2 and 3 intermediate between these classifications.  Diagnostic categories were defined as 
described in the National Toxicology Program Non-neoplastic Lesion Atlas (Cesta et al., 2014) 
(Seely and Brix 2014, Maronpot 2014) and the International Harmonization of Nomenclature and 
Diagnostic Criteria for Lesions in Rats and Mice (INHAND) Project. (Frazier et al., 
2012). Although several histological findings were initially identified across all the populations, 
we removed spontaneous lesions that were inconsistent both within each strain or population and 
treatment from the analysis. We focused on the three histopathological findings that were more 
consistent in the liver and kidney across the different populations. These were chronic progressive 
nephropathy, tubular epithelial vacuolation, and tubular epithelial karyomegaly in the kidney, and 
centrilobular hypertrophy and karyomegaly, focal inflammation, and apoptosis or necrosis in the 
liver. A composite histopathology score was calculated for each animal by summing individual 
scores for each lesion category for each tissue. 
III. Results   
Oxidative metabolite levels of TCE in tissues.  TCA is a major oxidative metabolite of TCE 
which has been shown to drive hepatocarcinogenesis via activation of peroxisome proliferation-
activating receptor alpha (PPARα) in rodents (Lash et al., 2014) . Previous studies in classical 
inbred lines and CC strains have shown strong positive correlation between liver TCA levels and 
PPARα-responsive genes suggesting that individuals with higher levels of TCA may be relatively 
more susceptible to PPARα-driven adverse effects in a population (Venkatratnam et al., 2017; 
Yoo, Bradford, Kosyk, Uehara, et al., 2015). In this study, a more than 10-fold difference in liver 
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and kidney TCA levels was observed between strains within the CC and CC-RIX populations 
administered with TCE (240 mg/kg) (Figure 4.1). We also observed that within the CC and CC-
RIX populations inter-strain variability was 10-foldwas greater than intra-strain variability. 
Interestingly, the extent of variability in liver and kidney TCA levels was comparable between 
B6C3F1 and DO mice (Figure 1). Although several strains from different populations showed 
large variability in TCA levels, in comparison to B6C3F1 no statistical significance was observed 
in hepatic and renal TCA levels (data not shown).  
Renal injury in different populations. KIM-1 is a known marker for proximal tubular 
damage in the kidney (Han, Bailly, Abichandani, Thadhani, & Bonventre, 2002). As classical 
mouse models do not reflect kidney injury with TCE exposures as seen in humans (Rusyn et al., 
2014), we measured KIM-1 levels from different mouse populations to evaluate the role of genetic 
differences in eliciting proximal tubular injury. KIM-1 levels between vehicle- and TCE-treated 
(240 mg/kg) mice were found to be less than 5-fold across strains but the differences within the 
CC and CC-RIX populations were appreciably larger than B6C3F1 and DO mice (Figure 2). 
Strain and population differences in basal hematological, hematopoietic, and 
physiological endpoints.    
Information on Complete Blood Count (CBC), bone marrow histopathology, and organ 
weights is often used to identify hazard and assess toxicodynamic effects of chemicals in a 90-day 
oral toxicity study. To understand whether genetic background has an influence on these biological 
endpoints we compared inter-strain differences for all the endpoints.  We observed that 15 out of 
20 hematological end points demonstrated significant differences across strains (Figure 3). 
Similarly, 9 out of 17 hematopoietic endpoints and all the other physiological endpoints were 
95 
 
significantly different across strains (Figure 3). Next, we also compared the extent of inter- versus 
intra-strain variability for all the endpoints (Figure 4). We observed that for majority of these 
endpoints inter-strain variability is greater than intra-strain variability (Figure 4).   
To identify the population model that offers the most diverse responses we compared 
coefficient of variation (CV) for all the endpoints by population. We observed that CC and CC-
RIX populations showed maximum diversity for 37 out of 44 endpoints (Figure 5). The DO 
population showed largest variability in responses among 5 out of 44 endpoints and also 2 out of 
44 endpoints were highly variable in B6C3F1. As expected, B6C3F1 displayed the lowest CVs for 
more than 50% of the endpoints. Interestingly, the DO mice also showed the lowest CVs for several 
endpoints. Another key finding was that no significant differences between B6C3F1 and DO mice 
were observed in their responses for all the physiological endpoints except for one hematopoietic 
endpoint. 
Among the endpoints that demonstrated significant inter-strain variability we directly 
compared the CVs of organ weights, body weights and organ-to-body weight ratios within each 
population. Changes in organ weights and organ-to-body weight ratios often provide information 
on target organ and treatment effects. We found that weights of gonadal fat deposit showed large 
CV within the CC-RIX population and showed appreciable inter-strain variability (Figures 4 and 
6). On the other hand, liver-to-body and kidney-to-body weight ratios demonstrated smaller CV 
within populations despite significant inter-strain variability (Figure 4 and 6).  
A similar trend was observed in hematological endpoints. For example, we observed that 
relatively higher variability in the percentage of neutrophils among the CC and CC-RIX 
populations in comparison to B6C3F1 and DO (Figure 7). However, other hematological 
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parameters such as relative percentage of lymphocytes and basal mean corpuscle volumes showed 
comparable variability across CC, CC-RIX, and DO populations. Hematopoietic endpoints such 
as percentages of lymphocytes and myeloid, and myeloid to erythroid ratios showed comparable 
variability across all mouse populations (Figure 8).     
Histopathological assessments of liver and kidney sections.  We observed some 
histopathological lesions showed high background incidences in specific strains and populations. 
For instance, in the kidney there was a high incidence of tubular epithelial vacuolation exclusively 
in B6C3F1 mice (Supplemental Table 1). Similarly, appreciable levels of chronic progressive 
nephropathy was observed across the CC population in comparison to the B6C3F1, CC-RIX 
population, and DO population (Supplemental Table 1). It is noteworthy that a majority of animals 
from the CC-RIX and DO populations showed little to no background incidences of any lesions in 
the kidney (Figure 9). Due to the higher incidence of tubular epithelial vacuolation in B6C3F1 
total histopathological scores in kidney were significantly different compared to DO and a few 
strains within CC population (Figure 9). In the liver, centrilobular hypertrophy and karyomegaly 
was found across the different populations and B6C3F1 (Supplemental Table 1). This resulted in 
higher total histopathological scores in liver for all the vehicle treated mice.   
Dose-response assessments of hematological and biological markers of toxicity. Dose-
response relationships are often conducted using toxicity endpoints to derive point of departures 
(PoDs) and establish safe levels of exposures. In our study we observed more than 10-fold 
differences in dose-response derived slopes for several CBC parameters within the CC and CC-
RIX populations (Figure 10). Interestingly, we also observed differences in slope direction for 
many markers suggesting that qualitative differences in such toxicodynamic responses may also 
exist within the CC and CC-RIX populations.  
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IV. Discussion    
Rodent testing has been the historical approach to assess adverse or pharmacological effects 
of chemicals that are either natural or anthropogenic. There is a need to develop models in these 
species that reflect larger variability in phenotypic and toxicodynamic effects to better identify 
hazard and improve precision in dose-response assessments. It is generally accepted that inbred 
strains of rodents minimize intra-strain variability in toxicological responses due to their genetic 
homogeneity. The F1 hybrid rodent models are reproducible and offer relatively larger genetic 
variability than inbred lines. Outbred stocks offer large variability in their responses due to batch-
to-batch differences in their genetic makeup. Despite fundamental differences in their genetic 
architecture, there is a need to compare inter-strain and intra-strain variability to account for 
variability in responses driven by genetic background. In this study, we aimed to incorporate 
different genetically-diverse mouse populations to better evaluate variability in metabolism and 
toxic effects, improve dose-response assessments, and identify an appropriate population model 
that may be better suited than B6C3F1 in future toxicity study designs. Despite the highly diverse 
toxicity endpoints that are routinely assessed in toxicity screenings, this investigation focused on 
hematological, hematopoietic, hepatic, nephrotic, and physiological endpoints relevant to our case 
study toxicant TCE. 
We observed highly diverse oxidative metabolism of TCE as measured by TCA levels within 
the CC and CC-RIXs in comparison to the B6C3F1 revealing that toxicokinetic responses maybe 
strongly driven by genetic background. This trend was also consistent with previous studies with 
chlorinated solvents using CC model (Cichocki et al., 2017; Venkatratnam et al., 2017).  A novel 
finding in this analysis is that population variability in liver and kidney TCA levels within the DO 
population was comparable to the B6C3F1. Despite the fact that the number of DO mice in each 
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treatment group was identical or comparable to the number of strains in the CC-RIX and CC, poor 
diversity in TCA levels in different tissues was observed in the DO population. One major reason 
for this is that the DO mice utilized in this study may lack the genetic diversity needed to compare 
with the CC and CC-RIX populations. To achieve comparable genetic diversity a large number of 
DO mice may need to be incorporated within each dose group. As previously observed (French et 
al., 2015), the total number of mice would be much larger than the current requirements of pre-
chronic studies. Also, due to batch to batch differences in the genetic diversity represented in DO 
population it may be challenging to achieve reproducibility and consistency in the toxicity 
findings.           
 Inter-strain differences in peripheral blood count values are known to exist suggesting that 
baseline levels of these parameters may determine degree of variability in hematotoxic effects 
upon chemical exposures (Kile, Mason-Garrison, & Justice, 2003). Previous studies have 
associated TCE with hematopoietic alterations, decreased lymphocytic counts, and B-cell 
activation (Bassig et al., 2016; Lan et al., 2010). We also observed that across the different 
hematological, hematopoietic, and physiological endpoints, the majority of the phenotypes showed 
large basal differences within CC and CC-RIX populations compared to B6C3F1 and DO. Further, 
most of the endpoints demonstrated significant basal inter-strain differences across the populations 
informing the need to incorporate population approaches to address variability in these responses. 
Evaluating variability in these responses not only sheds light on toxic markers that are strongly 
influenced by genetic background but also shows the importance of conducting safety assessments 
in population-based models instead of single strain models. 
 Dose response assessments often aim to derive a PoD value which corresponds to a 
particular dose at which the toxic outcome occurs or is perceived to occur. Uncertainty factors are 
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often employed to address data gaps in variability in PoDs of toxicokinetic and toxicodynamic 
responses. Experimental data to address this variability in apical endpoints are often unavailable 
or unusable due to concerns with study design, route of administration of chemicals, and selection 
and spacing of doses. A previous study with the CC model showed more than 10-fold inter-strain 
differences in transcriptional PoDs suggesting that these differences may be consistent or greater 
in traditional toxicity endpoints from pre-chronic and chronic studies (Venkatratnam et al., 2018). 
In this study, dose-response assessments of biological and hematological endpoints revealed that 
qualitative differences in PoDs due to differences in genetic background among individuals in CC 
and CC-RIX populations. Next, inter-strain differences in the PoDs for some endpoints varied by 
more than 10-fold, suggesting that default safety factors may be underestimating risk associated 
with exposures. These experimental data provide strong evidences for incorporation of population-
approaches in toxicity screening to better characterize variability in chemical responses and also 
select potentially susceptible strains for chronic study assessments. 
Histopathological examination of tissues is critical in identifying hazard and the target 
organ of toxicity. It is well known that certain strains are more prone to background lesions than 
others (Igarashi et al., 2013). There are clear differences in basal incidences of tubular epithelial 
vacuolation between B6C3F1 and individual strains from the CC and DO populations 
demonstrating that genetic background can have profound effect on these lesions.  
Based on the overall findings from this study we observe that the CC and CC-RIX 
populations offer large diversity in their responses to TCE exposures compared to B6C3F1 and 
DO. Despite the outcomes of this study, incorporation of population based rodent models into 
toxicity testing are not without limitations. First, chronic studies are often expensive due cost of 
purchasing animals, recruitment of pathologist and staff, and ancillary services. Incorporating   
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population-approaches to current chronic study designs will be both tedious and expensive. Next, 
information on survivability of strains from the CC and CC-RIX populations throughout a two-
year cancer bioassay is unavailable, limiting its use in chronic cancer bioassays. Third, background 
incidence of lesions and other health issues associated with selected susceptible strains needs to 
be made more publicly available as additional data is generated. 
In summary, this study shows promising results for incorporating population-based 
approaches in current toxicity study designs to address critical gaps in dose-response assessments 
and other aspects of risk assessment. Our study identifies CC and CC-RIX populations as useful 
population models that offer large diversity in responses that are routinely evaluated in safety 
assessments. Despite current challenges with these models, proper data curation and 
commercialization of these models may facilitate their use in the toxicology community in the near 
future.           
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V. Figures and Table 
Figure 4.1. Box and whisker plots of liver and kidney TCA levels in CC, CC-RIX, and DO 
populations in comparison to B6C3F1. The horizontal line is the median and the box represents 
1st and 3rd quartile ranges. The whiskers are the standard error of mean.  
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Figure 4.2. Line graph of average KIM-1 levels in vehicle (black circles) - and TCE (240 mg/kg, 
red circles) -treated CC, CC-RIX, and DO populations in comparison to B6C3F1.  
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Figure 4.3. Line graph displaying negative log10 p values for inter-strain variability across CC, 
CC-RIX, and DO populations, and B6C3F1. The dashed line represents the threshold value of p 
<0.05. 
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Figure 4.4. Bar graph representing coefficient of variation within CC, CC-RIX, and DO 
populations compared to B6C3F1 for different endpoints.  
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Figure 4.5. Bar graph comparing inter (red bar) - versus intra (blue bar)-strain variability for all 
the endpoints in all mouse populations and B6C3F1. *, **, and *** represents endpoints with 
significant (p values ≤ 0.05, ≤ 0.01, and ≤ 0.001) inter-strain differences.  
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Figure 4.6. Box plots showing coefficient of variation on physiological endpoints with statistically-
significant inter-strain differences in CC, CC-RIX, and DO populations, and B6C3F1. The 
horizontal line is the median and the box represents 1st and 3rd quartile ranges. 
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Figure 4.7. Box plots showing coefficient of variation on hematological endpoints with 
statistically-significant inter-strain differences in CC, CC-RIX, and DO populations, and B6C3F1. 
The horizontal line is the median and the box represents 1st and 3rd quartile ranges. 
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Figure 4.8. Box plots showing coefficient of variation on hematopoietic endpoints with 
statistically-significant inter-strain differences in CC, CC-RIX, and DO populations, and B6C3F1. 
The horizontal line is the median and the box represents 1st and 3rd quartile ranges. 
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Figure 4.9. Box-plots showing total histopathological scores of CC, CC-RIX, and DO populations, 
and B6C3F1.  ‘+’ sign represents the mean and the box is 1st and 3rd quartile ranges. The whiskers 
represents 5-95 percentile. 
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Figure 4.10. Ten percent change in the slope estimate per mg/kg per day dose of endpoints that 
demonstrated significant inter-strain differences across populations. Error bars represents 95% 
percent confidence interval. 
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Supplemental Table 4.1. Histopathological scoring of liver and kidney among CC, CC-RIX, and 
DO populations, and B6C3F1 treated with vehicle or TCE (240 mg/kg).  
Strain TCE 
dose 
(mg/kg) 
Chronic 
Progressive 
nephropathy 
Tubular 
epithelial 
vacuolation 
Tubular 
epithelial 
karyomegaly 
Total 
kidney 
score 
Centrilobular 
hypertrophy 
and 
karyomegaly 
Focal 
Inflammation 
Apoptosis
/Necrosis 
Total  
liver 
score 
B6C3F1 0 0 2 0 2 1 0 0 1 
B6C3F1 0 0 2 0 2 1 0 0 1 
B6C3F1 0 0 2 0 2 1 0 0 1 
B6C3F1 0 0 2 0 2 1 0 0 1 
B6C3F1 0 0 2 0 2 1 2 0 3 
B6C3F1 0 0 2 0 2 0 0 0 0 
B6C3F1 0 0 3 0 3 0 0 0 0 
B6C3F1 0 0 3 0 3 0 0 0 0 
B6C3F1 0 0 2 0 2 0 0 0 0 
B6C3F1 0 0 3 0 3 1 0 0 1 
CC_CC042/
GeniUnc 
0 0 0 0 0 1 0 0 1 
CC_CC042/
GeniUnc 
0 0 0 0 0 1 0 0 1 
CC_CC042/
GeniUnc 
0 0 0 0 0 1 0 0 1 
CC_CC042/
GeniUnc 
0 0 0 0 0 2 0 0 2 
CC_CC042/
GeniUnc 
0 0 0 0 0 2 0 0 2 
CC_CC042/
GeniUnc 
0 0 0 0 0 1 0 0 1 
CC_CC042/
GeniUnc 
0 0 0 0 0 2 0 0 2 
CC032/Geni
Unc 
0 0 0 0 0 0 0 0 0 
CC032/Geni
Unc 
0 0 0 0 0 1 0 0 1 
CC032/Geni
Unc 
0 0 0 0 0 1 0 0 1 
CC032/Geni
Unc 
0 1 0 0 1 0 0 1 1 
CC012/Geni
Unc 
0 1 0 0 1 1 1 0 2 
CC012/Geni
Unc 
0 1 0 0 1 0 0 0 0 
CC012/Geni
Unc 
0 1 0 0 1 0 1 0 1 
CC012/Geni
Unc 
0 0 0 0 0 0 0 2 2 
CC012/Geni
Unc 
0 1 0 0 1 0 1 1 2 
CC012/Geni
Unc 
0 0 0 0 0 0 1 1 2 
CC028/Geni
Unc 
0 0 0 0 0 0 0 0 0 
CC028/Geni
Unc 
0 2 0 0 2 1 1 0 2 
CC028/Geni
Unc 
0 0 0 0 0 1 0 0 1 
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CC028/Geni
Unc 
0 1 0 0 1 2 1 0 3 
CC010/Geni
Unc 
0 2 0 0 2 0 0 0 0 
CC010/Geni
Unc 
0 0 0 0 0 1 0 0 1 
CC010/Geni
Unc 
0 0 0 0 0 1 0 0 1 
CC010/Geni
Unc 
0 1 0 1 2 1 0 0 1 
CC010/Geni
Unc 
0 1 0 0 1 1 0 0 1 
CC033/Geni
Unc 
0 0 0 0 0 0 1 0 1 
CC033/Geni
Unc 
0 0 0 0 0 0 0 0 0 
CC033/Geni
Unc 
0 0 0 0 0 0 2 0 2 
CC033/Geni
Unc 
0 0 0 0 0 1 0 0 1 
CC005/TauU
nc 
0 1 0 0 1 0 1 0 1 
CC005/TauU
nc 
0 0 0 0 0 1 0 0 1 
CC005/TauU
nc 
0 1 0 0 1 0 0 0 0 
CC005/TauU
nc 
0 1 0 0 1 1 0 0 1 
CC005/TauU
nc 
0 2 0 0 2 0 0 0 0 
CC006/TauU
nc 
0 0 0 0 0 2 0 0 2 
CC006/TauU
nc 
0 0 0 0 0 0 0 0 0 
CC006/TauU
nc 
0 0 0 0 0 2 1 0 3 
CC006/TauU
nc 
0 0 0 0 0 2 2 0 4 
CC039/Unc 0 1 0 0 1 1 0 1 2 
CC039/Unc 0 1 0 0 1 1 0 0 1 
CC039/Unc 0 1 0 0 1 1 3 0 4 
CC039/Unc 0 1 0 0 1 0 0 0 0 
CC039/Unc 0 1 0 1 2 1 0 0 1 
CC036/Unc 0 1 1 0 2 1 1 0 2 
CC036/Unc 0 1 0 0 1 0 0 0 0 
CC036/Unc 0 1 0 1 2 2 2 1 5 
CC036/Unc 0 1 0 0 1 0 1 0 1 
CC036/Unc 0 0 1 0 1 1 0 0 1 
DO 0 0 0 0 0 2 0 0 2 
DO 0 0 1 0 1 1 0 0 1 
DO 0 1 0 0 1 2 0 0 2 
DO 0 0 0 0 0 1 0 0 1 
DO 0 0 0 0 0 1 1 1 3 
DO 0 0 0 0 0 0 1 0 1 
DO 0 0 0 0 0 2 0 0 2 
DO 0 0 0 1 1 0 1 0 1 
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DO 0 0 0 0 0 1 0 0 1 
DO 0 0 0 0 0 1 0 0 1 
CC055/TauU
nc x 
CC006/TauU
nc 
0 0 0 0 0 1 1 0 2 
CC071/TauU
nc x 
CC053/Unc 
0 0 0 0 0 0 0 0 0 
CC008/Geni
Unc x 
CC018/Unc 
0 0 0 0 0 1 0 0 1 
CC060/Unc 
x 
CC037/TauU
nc 
0 0 0 0 0 0 0 0 0 
CC040/TauU
nc x 
CC015/Unc 
0 0 0 0 0 1 0 0 1 
CC040/TauU
nc x 
CC015/Unc 
0 0 0 0 0 1 0 0 1 
CC001/Unc 
x 
CC074/Unc 
0 0 0 0 0 1 0 0 1 
CC001/Unc 
x 
CC074/Unc 
0 0 0 0 0 1 0 0 1 
CC062/Unc 
x 
CC072/TauU
nc 
0 0 0 0 0 1 0 0 1 
CC062/Unc 
x 
CC072/TauU
nc 
0 0 0 0 0 2 0 0 2 
CC062/Unc 
x 
CC072/TauU
nc 
0 1 0 0 1 2 0 0 2 
CC027/Geni
Unc x 
CC036/Unc 
0 0 0 0 0 0 0 0 0 
B6C3F1 240 0 1 0 1 2 1 0 3 
B6C3F1 240 0 2 0 2 1 0 0 1 
B6C3F1 240 0 0 0 0 1 0 0 1 
B6C3F1 240 0 2 0 2 1 0 0 1 
B6C3F1 240 0 2 0 2 1 0 0 1 
B6C3F1 240 1 2 1 4 1 1 0 2 
B6C3F1 240 0 2 0 2 1 0 0 1 
B6C3F1 240 0 2 1 3 1 0 0 1 
B6C3F1 240 0 2 0 2 1 0 0 1 
B6C3F1 240 0 2 0 2 1 0 0 1 
CC042/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC042/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC042/Geni
Unc 
240 0 0 0 0 0 1 2 3 
CC042/Geni
Unc 
240 0 0 0 0 2 0 0 2 
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CC032/Geni
Unc 
240 1 0 0 1 1 0 0 1 
CC032/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC032/Geni
Unc 
240 0 0 0 0 2 2 0 4 
CC032/Geni
Unc 
240 1 0 0 1 1 1 0 2 
CC012/Geni
Unc 
240 0 0 0 0 0 0 0 0 
CC012/Geni
Unc 
240 0 0 0 0 0 0 0 0 
CC012/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC012/Geni
Unc 
240 0 0 0 0 2 1 0 3 
CC028/Geni
Unc 
240 1 0 0 1 2 1 0 3 
CC028/Geni
Unc 
240 1 0 0 1 1 0 0 1 
CC028/Geni
Unc 
240 2 0 0 2 2 0 0 2 
CC028/Geni
Unc 
240 0 0 0 0 2 0 0 2 
CC010/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC010/Geni
Unc 
240 1 0 0 1 1 0 0 1 
CC010/Geni
Unc 
240 1 0 0 1 1 0 0 1 
CC010/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC010/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC033/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC033/Geni
Unc 
240 0 0 0 0 1 0 0 1 
CC033/Geni
Unc 
240 0 0 0 0 0 0 0 0 
CC005/TauU
nc 
240 1 0 0 1 1 2 0 3 
CC005/TauU
nc 
240 1 0 0 1 1 0 0 1 
CC005/TauU
nc 
240 0 0 0 0 0 0 0 0 
CC005/TauU
nc 
240 1 0 0 1 1 0 0 1 
CC005/TauU
nc 
240 1 0 0 1 2 0 0 2 
CC006/TauU
nc 
240 1 0 0 1 1 1 0 2 
CC006/TauU
nc 
240 0 0 1 1 2 1 0 3 
CC006/TauU
nc 
240 0 0 2 2 2 1 0 3 
CC039/Unc 240 1 0 0 1 1 0 0 1 
CC039/Unc 240 1 0 0 1 1 0 0 1 
CC039/Unc 240 1 1 0 2 0 0 0 0 
CC039/Unc 240 0 1 0 1 1 0 0 1 
CC036/Unc 240 1 0 0 1 2 1 0 3 
CC036/Unc 240 0 0 0 0 2 0 0 2 
CC036/Unc 240 1 0 0 1 2 0 0 2 
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CC036/Unc 240 1 0 0 1 2 1 0 3 
CC036/Unc 240 0 0 0 0 1 1 0 2 
DO 240 0 0 0 0 1 1 0 2 
DO 240 0 0 0 0 1 0 0 1 
DO 240 0 0 0 0 1 0 0 1 
DO 240 0 0 0 0 1 1 0 2 
DO 240 0 0 0 0 1 0 0 1 
DO 240 0 0 0 0 0 1 0 1 
DO 240 1 0 0 1 1 0 0 1 
DO 240 0 0 0 0 2 1 0 3 
DO 240 0 0 0 0 0 0 0 0 
CC055/TauU
nc x 
CC006/TauU
nc 
240 0 0 0 0 1 0 0 1 
CC055/TauU
nc x 
CC006/TauU
nc 
240 0 0 0 0 2 0 0 2 
CC071/TauU
nc x 
CC053/Unc 
240 0 0 0 0 0 0 0 0 
CC071/TauU
nc x 
CC053/Unc 
240 0 0 0 0 0 0 0 0 
CC008/Geni
Unc x 
CC018/Unc 
240 0 0 0 0 1 0 0 1 
CC008/Geni
Unc x 
CC018/Unc 
240 1 0 0 1 0 0 0 0 
CC060/Unc 
x 
CC037/TauU
nc 
240 1 0 0 1 0 0 0 0 
CC040/TauU
nc x 
CC015/Unc 
240 1 0 0 1 1 0 1 2 
CC040/TauU
nc x 
CC015/Unc 
240 1 0 0 1 2 1 0 3 
CC001/Unc 
x 
CC074/Unc 
240 0 0 0 0 2 1 0 3 
CC001/Unc 
x 
CC074/Unc 
240 0 0 0 0 2 0 0 2 
CC062/Unc 
x 
CC072/TauU
nc 
240 0 0 0 0 1 0 0 1 
CC062/Unc 
x 
CC072/TauU
nc 
240 0 0 0 0 2 0 0 2 
CC062/Unc 
x 
CC072/TauU
nc 
240 0 0 0 0 2 0 0 2 
CC027/Geni
Unc x 
CC036/Unc 
240 0 0 0 0 0 0 0 0 
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CC027/Geni
Unc x 
CC036/Unc 
240 0 0 0 0 1 0 0 1 
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CHAPTER 5: DISCUSSION 
I. Conclusions  
Hazard identification and dose response assessments are key steps in chemical risk 
assessment that aim to identify and characterize potential adverse effects with exposure to 
stressors. Due to technological and scientific advances, the approaches employed in chemical 
assessments have evolved over time. For example, in vitro, in silico and tissue chip models are 
often envisioned to replace or reduce animal based-testing (Esch, King, & Shuler, 2011; National 
Research Council, 2007). The U.S. Environmental Agency’s Toxicity Forecaster (ToxCast™) 
program implements high- throughput screening approaches that identifies bioactivity profiles 
with exposures to rank chemicals for further testing (Benigni, 2013; Dix et al., 2007). The 
Toxicology Testing in the 21st Century (Tox21) collaboration aims to establish a database 
providing bioactivity information on more than 10,000 compounds for prioritizing chemicals for 
hazard identification (Tice, Austin, Kavlock, & Bucher, 2013). Tissue chips are biomechanical 
devices comprising of living cells within silicon engraved systems that are perceived to be 
physiologically closer to in vivo models compared to classical cell based- models. Tissue chips are 
currently being tested for their utility in hazard identification in both industry and academia 
(Willyard, 2017). Quantitative structure-activity relationships (QSAR) are based on computational 
models that predict potential bioactivity of an analyte based on available data on structurally-
similar chemicals (Zhang et al., 2013). Although the above described approaches have vastly 
helped in providing experimental or predicted data to understand chemical-target interactions and 
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aid with the regulatory decision making processes, they fail to address population variability in 
such interactions that lead to differences in degree of adverse reactions as seen in humans.          
Addressing population variability in toxic responses is a persistent challenge in chemical 
risk assessments (Zeise et al., 2013). Population-based in vitro models are emerging resources that 
have been recently implemented in biomedical research and toxicological studies (Harrill & 
McAllister, 2017; Siva, 2008). The Lock et al. 2012 study also showed the utility of population–
based models to conduct high throughput screening of chemicals to evaluate inter-individual 
differences in dose-response assessment and its relevance in addressing the issue of 
subpopulations. The 1000 Genomes Project is a collaborative effort that aimed to catalogue genetic 
variations that occur at relatively low frequencies in coding regions of genes. This resource has 
been previously used to characterize inter-individual differences in hazard and to conduct 
population level dose-response assessments. For instance, the (Abdo, Xia, et al., 2015) study 
demonstrated the feasibility to conduct high throughput screening of cytotoxic responses to 179 
chemicals in immortalized lymphoblastoid cell lines from 1000 donors. Further, the use of in vitro 
population models enabled high precision genome wide association mapping to identify genetic 
loci associated with toxicity outcomes thereby providing information on novel mechanisms driving 
variability in adverse effects (Abdo, Wetmore, et al., 2015). Although the use of population-based 
in vitro models offer several advantages than traditional cell-based approaches, rodent models are 
still considered a gold standard for toxicity testing.  
Population-based mouse models are often implemented in research with a focus on 
understanding genotype-phenotype associations. Several studies have demonstrated the utility of 
population-based mouse models in systems genetics, addressing variability in toxicokinetic and 
toxicodynamic responses, and identifying susceptible strains that accurately mimic adverse 
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responses as seen in humans (Cichocki et al., 2017; French et al., 2015; Rasmussen et al., 2014). 
Despite available information on population-based rodent models, their utility in addressing 
variability and uncertainty in hazard identification and dose-response assessments have not been 
extensively explored. This dissertation focused on the role of population-based rodent models in 
toxicity testing using trichloroethylene as a case study toxicant.  
II. Summary of Findings 
In Specific Aim 1, we observed that the CC model demonstrates large diversity in TCE 
toxicokinetic and toxicodynamic responses compared to classical inbred lines but comparable to 
humans. One interesting finding from this study was that levels of hepatic TCA significantly 
correlated with hepatic gene expression of Acox1 but did not correlate with protein expression or 
activity levels of known TCE metabolizing enzymes demonstrating that TCA is a complex trait 
involving multiple pathways of formation, transformation, and elimination. This evidence also 
suggests the simple hypothesis that gene environment interactions may also apply for toxicokinetic 
responses. The mosaic representation of the founder alleles in the CC model facilitated genetic 
mapping with improved precision in identifying novel markers driving variability in TCE 
metabolism and toxicodynamics.  
In Specific Aim 2, we identified genetic background as profoundly affecting gene 
expression compared to dose or interaction effects. We also observed that expression of genes 
significantly influenced by TCE were also influenced by TCA suggesting that PPARα signaling 
plays a major role in liver transcriptional responses. Pathway enrichment analysis revealed several 
pathways significantly perturbed within the CC population with 10-fold differences in their median 
PoDs. Also, appreciable differences within the CC population in median PoDs of aggregated 
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pathways enabled identification of potential susceptible and resistant strains for pre-chronic and 
chronic studies. Expression-quantitative trait loci (eQTL) analysis identified a linkage between 
liver expression of Fitm2 and TCA levels. Collectively, these data demonstrate the potential of the 
CC model for conducting systems genetics. Another interesting finding that CC population enabled 
estimating variability in transcriptional PoDs and demonstrates reasonable correlation with PoDs 
of apical endpoints from previous pre-chronic and chronic studies. 
In Specific Aim 3, we tested the feasibility of incorporating different population-based 
rodent models in a standard 90-day oral toxicity study to directly compare variability in TCE 
toxicokinetic and toxicodynamic responses in population-based experiments with variability in the 
B6C3F1 strain. We identified CC and CC-RIX as demonstrating large variability in liver and 
kidney TCA levels in comparison to B6C3F1. We also observed that basal variability in several 
physiological, hematological, and hematopoietic endpoints were highly variable within the CC and 
CC-RIX populations. Dose-response assessments revealed that 10-fold differences in PoDs of few 
endpoints between strains within CC and CC-RIX populations. In addition, qualitative differences 
in dose response relationships were also marked among several strains within the CC and CC-RIX 
populations.  Interestingly, the variability within the DO population was comparable to intra-strain 
variability of the B6C3F1. Results from this study identifies strains from CC and CC-RIX as 
diverse responders to TCE and which could be used to replace B6C3F1 in chronic studies. In 
summary, the use of CC model and other population-based mouse models have provided 
experimental data to address significant gaps of knowledge relevant to human variability in risk 
assessment.  
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III. Significance  
One of the critical challenges in risk assessment is addressing variability and uncertainty 
in hazard identification and dose-response assessments. Several outcomes from of this dissertation 
shed light on using population-based models to address these concerns. Firstly, differences in 
mechanisms of toxicity within a population may lead to challenges in identifying the appropriate 
strain or model to conduct toxicity testing. Evidence from our studies show large diversity in 
responses for several toxicokinetic and toxicodynamic endpoints suggesting the possibility of 
susceptible individuals that maybe incorporated in chronic studies as an alternative to B6C3F1. 
Secondly, uncertainty in differences in toxicokinetic and toxicodynamic responses are historically 
addressed using uncertainty factors. A safety factor of 10 accounting for 3.3 fold-differences in 
toxicokinetic and toxicodynamic responses within a population is often used as a default in the 
absence of population-based data. This dissertation demonstrates that greater than 10-fold 
variability exists in TCE toxicokinetic and toxicodynamic responses in both single- and repeated-
dose studies suggesting that default assumptions maybe underestimating risk leading to inaccurate 
toxicity values. Thirdly, safety assessments have always been conducted with the assumption that 
susceptible individuals do exist in a population. However, often due to lack of data in these 
assessments it is difficult to directly compare individual- versus population - dose response 
relationships to ensure that the susceptible individuals are indeed protected from risk. Data from 
this dissertation identified genes associated with TCE toxicokinetics and toxicodynamics that are 
either highly variable or consistent in their responses among individuals in the CC population. This 
information is useful in interpreting biological endpoints that maybe strongly dependent on genetic 
background.  
122 
 
Efforts to integrate mechanistic and genetic data to address inter-individual variability in 
toxic responses are often limited due to cross-disciplinary research challenges. Population-based 
rodent models facilitate systems genetic tools to identify genetic variants driving variability in an 
endpoint. Further, use of gene expression data permits identification of all local and distal genetic 
interactions contributing to the variability of an endpoint. In this study, the CC model enabled 
identification of a link between expressions of Fitm2 that is driven by PPARα and TCA levels in 
the liver.           
    Hazard identification: Historically, single strains of rodents have often been used to 
assess hazard with exposures. Evidences from pharmacogenomics have shown vast differences in 
drug metabolizing capacity among individuals carrying genetic variants (W. E. Evans & Relling, 
2004). So it can be perceived that for any given toxicity endpoint there would exist susceptible and 
resistant strains in a population. Further, due to the diverse responses in a population certain strains 
may better reproduce the clinical manifestations as seen in susceptible groups or individuals in the 
human population. This dissertation provides experimental data that shows large variability in TCE 
oxidative metabolism and toxicodynamic responses in both single- and repeated-dose studies 
suggesting the existence of susceptible and resistant strains to toxicity upon chronic exposures.  As 
this dissertation focused on a single case study toxicant, selection of good or appropriate 
individuals for hazard identification maybe challenging for other chemicals. However, based on 
available toxicity data or structure-activity relationships chemicals can be broadly categorized 
based on their mechanisms of toxicity. For example, activation of PPARα-signaling in mice may 
contribute to hepatocarcinogenesis via non-genotoxic mechanisms. Thus, selection of strains with 
diverse levels of PPARα activators as metabolites or PPARα-responsive gene expression may 
represent a panel of genetically-diverse mice that serves as good models to enhance hazard 
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identification of potential PPARα agonists. Similarly, strains with diverse toxicokinetic activities 
can be selected to improve hazard identification of chemicals where adverse reactions are 
metabolism dependent.   
Dose-response assessments: Dose-response assessment is an essential component in the 
chemical risk assessment process and is conducted to derive PoDs. Sufficient data from this 
dissertation highlights the critical need to characterize individual- versus population-level 
differences in dose-response relationships. As toxic outcomes arise from chemical-host 
interactions genetic differences between hosts pose a challenge to characterize chemical-driven 
responses that are strongly dependent on dose, genetic background, or their combinatory effects. 
One significant finding from this dissertation is the strong influence of genetic background 
on toxicokinetic and toxicodynamic responses. As traditional dose-response assessments are often 
conducted in single strains, PoDs derived from these models may not be protective towards 
susceptible individuals or groups. Also, the effect of genetic background on all the routinely 
evaluated toxicity endpoints remains vastly unknown to make informed decision on the strain of 
choice for a given endpoint. Further, dose-response assessments from both single- and repeated-
dose studies in single strain rodent models have demonstrated not only quantitative differences but 
also qualitative differences in the derived PoDs. Consequently, there is uncertainty in the choice 
of single-strain model-based PoD for regulatory risk assessment. Population-based models will 
better characterize variability across strains in a population thereby address uncertainty in dose-
response assessments.   
Population-based 90-day oral toxicity study: The two-year cancer bioassay is considered 
as the gold standard for carcinogenicity. 90-day toxicity studies often provide preliminary toxicity 
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data on a test chemical to justify conducting chronic studies. As a single strain of rodents are often 
implemented in pre-chronic studies it is unrealistic that such models would represent susceptible 
individuals for all the chemicals and toxicity endpoints that requires investigation. Incorporation 
of population-based approaches in toxicity testing of chemicals would increase the likelihood of 
identifying susceptible strains that may be used for chronic studies. Further, population models 
would also help to characterize the role of genetic background in dose-response assessments. One 
major concern with population approaches is that sample size of the study designs may need to be 
increased to achieve adequate statistical power. However, Specific Aim 3 of this dissertation shows 
that population-based repeated toxicity studies can still be conducted without increasing the 
sample size of the studies. Such an approach helps address variability in chemical risk assessments.                   
IV. Limitations 
Although population models offer several advantages in addressing significant gaps in risk  
assessments, there are also limitations associated with using these models. First, population 
Although this dissertation highlights the significance of using population-based rodent approaches 
to address significant gaps in risk assessments, there are several considerations and limitations that 
need to be considered with these models. It is perceived that population-based rodent models 
facilitate systems genetic analysis, an approach to understand the flow of biological information 
controlling a trait or adverse outcome. Evidence from this dissertation demonstrate limitations in 
identifying genetic regions driving transcriptional changes contributing to adverse reaction. For 
instance, we identified a local genetic region associated with gene expression of Fitm2 that is 
associated with hepatic TCA levels. However, no association between distal genetic loci and gene 
expression profiles were found to draw conclusions on other genes and possibly gene-environment 
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interactions associated with TCA levels. These data suggest that depending on the complexity that 
underlie the phenotype or outcome of interest, systems genetic approaches maybe less effective in 
dissecting mechanistic associations in the flow of biological information.   
As the case study toxicant used in this dissertation is TCE, implications of using 
population-based rodent models from this dissertation should be carefully interpreted. Evidence 
from previous studies in classical inbred strains demonstrated large inter-strain differences in 
oxidative metabolism and toxicodynamics that were found to be much more pronounced in the 
population models. Further, these effects were then associated with several genetic loci that led to 
the identification of novel mechanisms of toxicity. However, not all inter-individual differences 
observed in an endpoint may be driven by genetics. Non-genetic factors such as environment, 
epigenetics, age, sex, and pre-existing conditions may also have a role in inter-individual 
differences in therapeutic or adverse outcomes.  
Next, statistical testing used in population models would be different in comparison to 
classical models. Pair-wise testing may be inappropriate as population models are similar to 
epidemiological studies. Thus, other statistical approaches such as random effect models or 
Bayesian approaches may be better suited for population models. In order to maintain existing 
sample sizes in traditional toxicity testing another trade off in population models would be to 
replace more biological replicates of one strain per dose group with few biological replicates of 
different strains per dose group.   
Lastly, population-based studies are often expensive and tedious. In order to conduct 
genetic mapping experiments with high precision a large panel of strains is often required to 
characterize variability in toxicodynamic and toxicokinetic responses. Further, certain polygenic 
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endpoints maybe highly complex so that even a large genetically-diverse population may fail to 
identify all molecular interactions contributing to inter-individual differences observed in the 
population. In the context of toxicity screening, knowledge on background lesions, survivability, 
and other pre-disposed health conditions in the strains within these models are yet to be fully 
characterized and curated. This information is useful for selecting strains for chronic studies. 
Reproducibility of the findings from non-reproducible population models is a significant concern 
that needs to be addressed in safety assessments. In summary, these limitations should be taken 
into consideration while designing and conducting population-based rodent studies. 
V. Future Studies 
Exposure Assessments: Exposure assessment is a major step in chemical risk assessments. 
This step aims in measuring the amount and duration of exposure to an agent. Exposure 
assessments are often conducted to calculate internal dose – the amount of chemical that is 
biologically available within the body. Previous studies in mouse diversity panels have 
demonstrated large differences in tissue-specific internal doses of TCE, and PBPK models have 
shown comparable estimates in variability between humans and mice (Bradford et al., 2011; Chiu 
et al., 2014a; Yoo, Bradford, Kosyk, Uehara, et al., 2015). One future direction would be to extent 
current PBPK models to include data from population-based mouse models. Such an approach can 
inform whether models such as CC are good surrogates for human population toxicokinetic 
variability.  
Two year cancer bioassay: The two-year cancer bioassay has been traditionally used to assess 
carcinogenic potential of chemicals. One approach to incorporate population-based rodent models 
in toxicity testing would be to select strains within the CC and CC-RIX populations from the pre-
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chronic study that are high and low responders to TCE exposures to conduct a chronic study. 
Another important study to further address uncertainty in assessments would be to conduct a single 
exposure toxicokinetic study using strains with diverse responses within the CC population. 
Comprehensive metabolite profiling of both oxidative and glutathione dependent metabolites can 
be incorporated into existing PBPK models to better assess inter-species differences in TCE 
metabolism. This approach would help test whether there is variability in the mechanisms of 
toxicity are driven by differences in genetic background. 
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